Clinical Study Protocol  R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 1 of 83 
CONFIDENTIAL  IND: Number:  [ADDRESS_406530]: 2017 -004921 -33 Regeneron Pharmaceuticals, Inc.  
Clinical Study Protocol  
A Randomized, Double -Blind, Placebo -Controlled, Multicenter Study to 
Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients 
with Pain due to Osteoarthritis of the Hip or Knee  
Compound:  Fasinumab  
Clinical Phase:  2 
Protocol Number:  R475 -OA-1758  
Protocol Version:  R475 -OA-1758 Amendment 2  
Amendment 2 Date of Issue:  See appended electronic signature [CONTACT_25073] 1 Date of Issue:  16 Jul 2018  
Original Date of Issue  20 Feb 2018  
Medical/Study Director:   
 
Regeneron Pharmaceuticals, Inc.  
[ADDRESS_406531]  
Tarrytown, NY [ZIP_CODE]  
 
 
 
 
 
 
VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00[STUDY_ID_REMOVED]

Clinical Study Protocol   R475 -OA-[ADDRESS_406532] been made to improve clarity.  The 
following table outlines the changes made to the protocol and the affected sections:  
Change and Rationale  Sections Changed  
Main Change:  
The criterion for detection of a change in nerve 
conduction velocity h as been revised from a de ficit of 
5 m/second to a deficit of >12% relative to the baseline 
value.  This update was made to allow the measurement 
of change from baseline to be relative to the patient’s 
size (eg, height and length of limb) and, thus, decreas e 
the potential of obtaining false -positive findings due to 
varying patient size.  Procedures for monitoring 
peripheral sensory adverse events of special interest 
have been updated accordingly.  Section  [IP_ADDRESS]  Peripheral Sensory Adverse Events  
Other Changes : 
Time frames have been added to the safety endpoints for 
clarity.  Clinical Study Protocol Synopsis , Endpoints  
Section  4.[ADDRESS_406533] 
practices (ie, updated protocol template text)  Clinical Study Protocol Synopsis , Endpoints   
Section  4.5 Anti-Drug Antibody Variables  
Section  10.3.4  Anti-Drug Antibody Analysis Set  
Section  10.4.6  Analysis of Anti -Drug Antibody Data  
Sectio n 14.5 Clinical Study Data Transparency  (section 
added)  
An additional reason for permanent discontinuation of 
study drug has been added, as follows:  
‘Per protocol repeat ed nerve conduction test that 
confirms results are not within the established 
parameters for peroneal, sural , or ulnar nerves, as per 
central reader assessment and the neurologist ’s 
evaluation that confirms the diagnosis of peripheral 
neuropathy .’ Section  [IP_ADDRESS]  Reasons for Permanent Discontinuation 
of Study Drug  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceutica ls, Inc.   Page 3 of 83 
CONFIDENTIAL  Minor edits were also made to this section.  
A statement has been added to clarify that patient -
reported outcome measures should be completed before 
all other assessments.  Table  1 Schedule of Events  
Section  8.1.1  Footnotes for the Schedule of Events  
Table  1, Footnote #22  
Section  [IP_ADDRESS]  Western Ontario and McMaster 
Universities Osteoarthritis Index  
Section  [IP_ADDRESS]  Survey of Autonomic Symptoms  
Section  [IP_ADDRESS]  Joint Pain Questionnaire  
Methotrexate has been added to the list of prohibited 
immunosuppressants.  Section  7.7.1  Prohibited Medications  
The scale used to assess the WOMAC index has been 
revised to the numerical rating scale (previously 
incorrectly cited as the Likert scale).  Section  [IP_ADDRESS]  Western Ontario and McMaster 
Universities Osteoarthritis Index  
RAVE Medidata Imaging System has been added to the 
list of electronic systems used in the study .  This is an 
electronic platform used to upload nerve conduction test 
wave forms for central reader review.  Section  11.[ADDRESS_406534] of Abbreviations and Definition of Terms  
Section  5.1.1  Screening and Pre-Randomization  
Section  5.1.2  Rescreening  
Section  6.2.2  Exclusion Criteria, #7  
Section  7.1 Investigational a nd Reference Treatments  
Section  [IP_ADDRESS]  Reasons for Temporary Discontinuation 
of Study Drug  
Table  1 Schedule of Events  
Section  8.1.1  Footnotes for the Schedule of Events  
Table  1, Footnote #8 , Footnote #19  
Section  [IP_ADDRESS]  Nerve Conduction  
Section  [IP_ADDRESS]  Laboratory Testing  
Section  10.4.5  Analysis of Drug Concentration Data  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceutica ls, Inc.   Page 4 of 83 
CONFIDENTIAL  Amendment 1  
The purpose of this amendment is to change the fasinumab 3 mg Q4W dose regimen to a 1 mg 
Q4W dose regimen because the 3 mg Q4W dose regimen is no longer being evaluated in the 
osteoarthritis (OA) pain program.  The [ADDRESS_406535] been made to improve study outcome 
measur es and for clarity. The following table outlines the changes made to the protocol and the 
affected sections:  
Change and Rationale  Sections Changed  
The 3 mg Q4W dose regimen has been removed and 
replaced with a 1 mg Q4W dose regimen.  Clinical Study Protoc ol Synopsis, Study Design, 
Treatments, Statistical Plan  
Section  1 Introduction  
Section  3.1.2  Rationale for Dose Selection  
Section  5.1.3  Randomization  
Section  5.1.4  Treatment Period  
Section  7.1 Investi gational and Reference Treatments  
Section  7.5 Method of Treatment Assignment  
Section  10.2 Justification of Sample Size  
The phone visit at week 1 has been changed to a site visit 
in order to obtain a more complete pharmacokinetic 
profile.  Table  1 Schedule of Events  
The exclusion criterion regarding carpal tunnel 
syndrome has been updated to include additional 
conditions that could interfere with the assessment of the 
primary endpoint.  Specifically, “Signs or symptoms of 
carpal tunnel syndrome within 6 months of the screening 
visit” has been updated to “History or presence of signs 
or symptoms of compression neuropathy, including 
carpal tunnel syndrome or sciatica.”  Section  6.2.2  Exclusion Criteria, #[ADDRESS_406536] be obtained before 
randomization can occur.  Clinical Study Protocol Synopsis, Study Design  
Section  5.1.1  Screening and Pre -Randomization  
Table  1 Schedule of Events  
Section  8.1.1  Footnotes for the Schedule of Events,  
Table  1 Footnote #[ADDRESS_406537] been listed in 
the Laboratory Testing section  Section  [IP_ADDRESS]  Laboratory Testing  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406538] of Abbreviations and Definitions of Terms  
Section  4.3 Additional Safety Endpoints  
Section  5.1.1  Screening and Pre -Randomization  
Section 5.1.2  Rescreening  
Section  6.2.2  Exclusion Criteria, #7  
Section  7.4.2  Local Injection Site Reactions  
Section  7.7.1  Prohibited Medications  
Section  7.7.2  Permitted Medications and Procedures  
Table  1, Schedule of Events  
Section  8.1.1  Footnotes for the Schedule of Events 
Table  1, Footnote #4  
Section  [IP_ADDRESS]  Diary Training  
Section  8.2.1 .9 Patient Education Brochures  
Section  [IP_ADDRESS]  Procedures to be Perf ormed Only in the 
Event of a Joint Replacement Surgery  
Section  9.4.3  Other Events that Require Accelerated 
Reporting to Sponsor  
Section  [IP_ADDRESS]  Adjudicat ed Arthropathy  
Section  [IP_ADDRESS]  Peripheral Sensory Adverse Events  
Section  10.3.3  Pharmacokinetic Analysis Set  
Section  10.4.3  Efficacy Analysis  
Section  10.4.5  Analysis of Drug Concentration Data  
Section  11.2 Electronic Systems  
Section  12.1 Monitoring of Study Sites  
 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406539] and Additional Imaging  ................................ ................ 28 
5.1.7.  Study Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ .28 
5.1.8.  End of Study Definition  ................................ ................................ .............................. 29 
5.2. Planned Interim Analysis  ................................ ................................ ............................ 29 
5.3. Study Committees  ................................ ................................ ................................ .......29 
5.3.1.  Independent Data Monitoring Committee  ................................ ................................ ..29 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 7 of 83 
CONFIDENTIAL  5.3.2.  Arthropathy Adjudication Committee  ................................ ................................ ........ 29 
6. SELECTION, WITHDRAWA L, AND REPLACEMENT O F PATIENTS  .............. 29 
6.1. Number of Patients Planned  ................................ ................................ ....................... 29 
6.2. Study Population  ................................ ................................ ................................ ......... 30 
6.2.1.  Inclusion  Criteria  ................................ ................................ ................................ ........ 30 
6.2.2.  Exclusion Criteria  ................................ ................................ ................................ .......31 
6.3. Premature Withdrawal from the Study  ................................ ................................ .......34 
6.4. Replacement of Patients  ................................ ................................ ............................. 35 
7. STUDY TREATMENTS ................................ ................................ ............................ 35 
7.1. Investigational and Reference Treatments  ................................ ................................ ..35 
7.2. Rescue Treatment  ................................ ................................ ................................ .......35 
7.3. Dose Modification and Study Treatment Discontinuation Rules  ............................... 36 
7.3.1.  Dose Modification  ................................ ................................ ................................ ......36 
7.3.2.  Study Drug Discontinuation  ................................ ................................ ....................... 36 
[IP_ADDRESS]. Reasons for Permanent Discontinuation of Study Drug  ................................ ............. 36 
[IP_ADDRESS].  Reasons for Temporary Discontinuation of Study Drug  ................................ ............ 38 
7.4. Management of Acute Reactions  ................................ ................................ ................ 38 
7.4.1.  Systemic Injection Reactions  ................................ ................................ ...................... 38 
7.4.2. Local Injection Site Reactions  ................................ ................................ .................... 38 
7.5. Method of Treatment Assignment  ................................ ................................ .............. 38 
7.5.1.  Blinding  ................................ ................................ ................................ ...................... 38 
7.5.2.  Emergency Unblinding  ................................ ................................ ............................... 39 
7.5.3.  Unblinding for Regulatory Reporting Purposes  ................................ ......................... 39 
7.6. Treatment Logistics and Accountability  ................................ ................................ .....39 
7.6.1.  Packaging, Labeling, and Storage  ................................ ................................ .............. 39 
7.6.2.  Supply and Disposition of Treatments  ................................ ................................ .......39 
7.6.3.  Treatment Accountability  ................................ ................................ ........................... 40 
7.6.4.  Treatment Compliance  ................................ ................................ ................................ 40 
7.7. Concomitant Medications and Procedures  ................................ ................................ .40 
7.7.1.  Prohibited Medications  ................................ ................................ ............................... 40 
7.7.2.  Permitted Medications and Procedures  ................................ ................................ ......41 
8. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  ................................ ......41 
8.1. Schedule of Events  ................................ ................................ ................................ .....41 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 8 of 83 
CONFIDENTIAL  8.1.1.  Footnot es for the Schedule of Events Table 1  ................................ ............................ 45 
8.1.2.  Footnotes for Table 2  - Follow -up Period for Patients Undergoing Joint 
Replacement Surgery  ................................ ................................ ................................ ..47 
8.1.3.  Early Termination Visit  ................................ ................................ .............................. 48 
8.1.4.  Unscheduled Visits  ................................ ................................ ................................ .....48 
8.2. Study Procedures  ................................ ................................ ................................ ........ 48 
8.2.1.  Procedures Performed Only at the Screening/Baseline Visit  ................................ .....48 
[IP_ADDRESS].  Main Study Informed Consent  ................................ ................................ .................... 48 
[IP_ADDRESS].  Genomics Sub -study Informed Consent  ................................ ................................ .....48 
[IP_ADDRESS].  Medical History  ................................ ................................ ................................ .......... 48 
[IP_ADDRESS].  Medication History  ................................ ................................ ................................ .....48 
[IP_ADDRESS].  Demographics  ................................ ................................ ................................ ............. 49 
[IP_ADDRESS].  Determination of Osteoarthritis  ................................ ................................ .................. 49 
[IP_ADDRESS].  Assessment of Childbearing Potential  ................................ ................................ ........ 49 
[IP_ADDRESS].  Diary Training  ................................ ................................ ................................ ............ 50 
[IP_ADDRESS].  Patie nt Education Brochures ................................ ................................ ....................... 50 
8.2.2.  Patient -Completed Assessments and Efficacy Procedures  ................................ ......... 50 
[IP_ADDRESS].  Western Ontario and McMaster Universities Osteoarthritis Index  ............................ 50 
8.2.3.  Neurological Assessments  ................................ ................................ .......................... 50 
8.2.3. 1. Nerve Conduction  ................................ ................................ ................................ .......50 
[IP_ADDRESS].  Neurological Examination (Full)  ................................ ................................ ................ 51 
[IP_ADDRESS].  Survey of Autonomic Symptoms  ................................ ................................ ................ 51 
[IP_ADDRESS].  Orthostatic Blood Pressure Assessment and Heart Rate  ................................ ............ 51 
8.2.4.  Safety Procedures  ................................ ................................ ................................ .......52 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 52 
[IP_ADDRESS].  Electrocardiogram  ................................ ................................ ................................ .......52 
[IP_ADDRESS].  Physical Examination and Body Weight  ................................ ................................ ....52 
[IP_ADDRESS].  Joint Pain Questionnaire  ................................ ................................ ............................. 52 
[IP_ADDRESS].  Imaging  ................................ ................................ ................................ ....................... 52 
[IP_ADDRESS].  End of Study Phone Contact [CONTACT_329095]  ................................ ................ 53 
[IP_ADDRESS].  Procedures to be Performed Only in the Event of a Joint Replacement 
Surgery  ................................ ................................ ................................ ........................ 53 
[IP_ADDRESS].  Laboratory Testing  ................................ ................................ ................................ ......54 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 9 of 83 
CONFIDENTIAL  [IP_ADDRESS].  Injection Site Evaluations  ................................ ................................ ........................... 56 
8.2.5.  Pharmacokinetic and Anti -Drug Antibody Procedures  ................................ .............. 56 
[IP_ADDRESS].  Drug Concentration Measurements and Samples  ................................ ....................... 56 
[IP_ADDRESS].  Anti-Drug Antibody Measurements and Samples  ................................ ...................... 56 
8.2.6.  Research Samples  ................................ ................................ ................................ .......56 
[IP_ADDRESS].  Biomarkers  ................................ ................................ ................................ .................. 56 
[IP_ADDRESS].  Future Bi omedical Research  ................................ ................................ ....................... 57 
[IP_ADDRESS].  Genomics Sub -study - Optional ................................ ................................ .................. [ADDRESS_406540]  ................................ .......................... 64 
[IP_ADDRESS].  Adjudicated Arthropathy  ................................ ................................ ............................ 64 
[IP_ADDRESS].  Sympathetic Nervous System Dysfunction  ................................ ................................ 65 
[IP_ADDRESS].  Peripheral Sensory Adverse Events  ................................ ................................ ............ 66 
[IP_ADDRESS].  Joint Replacement Surgery  ................................ ................................ ......................... 66 
9.7. Investigator Alert Notification  ................................ ................................ .................... 67 
10. STATISTICAL PLAN ................................ ................................ ................................ 67 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 10 of 83 
CONFIDENTIAL  10.1.  Statistical Hypothesis  ................................ ................................ ................................ ..67 
10.2.  Justification of Sample Size ................................ ................................ ........................ 67 
10.3.  Analysis Sets  ................................ ................................ ................................ ............... 68 
10.3.1.  Efficacy Analysis Set  ................................ ................................ ................................ ..68 
10.3.2.  Safety Analysis Set  ................................ ................................ ................................ .....68 
10.3.3.  Pharmacokinetic Analysis Set  ................................ ................................ .................... 68 
10.3.4.  Anti-Drug Antibody Analysis Set  ................................ ................................ .............. 68 
10.4.  Statistical Methods  ................................ ................................ ................................ ......68 
10.4.1.  Patient Disposition  ................................ ................................ ................................ ......68 
10.4.2.  Demography and Baseline Characteristics  ................................ ................................ .68 
10.4.3.  Efficacy Analysis  ................................ ................................ ................................ ........ 69 
10.4.4.  Safety Analysis  ................................ ................................ ................................ ........... 69 
[IP_ADDRESS].  Prim ary Safety Analysis  ................................ ................................ ............................. 69 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 70 
[IP_ADDRESS].  Other Safety  ................................ ................................ ................................ ................ 70 
[IP_ADDRESS].  Treatment Exposure  ................................ ................................ ................................ ....71 
[IP_ADDRESS].  Treatment Compliance  ................................ ................................ ................................ 71 
10.4.5.  Analysis of Drug Concentration Data  ................................ ................................ ......... 71 
10.4.6.  Analysis of Anti -Drug Antibody Data  ................................ ................................ ........ 71 
10.5.  Interim Analysis  ................................ ................................ ................................ .......... 72 
10.6.  Additional  Statistical Data Handling Conventions  ................................ ..................... 72 
10.7.  Statistical Considerations Surrounding the Premature Termination of a Study  ......... 72 
11. DATA MANAGEMENT AND ELECTRONIC SYSTEMS  ................................ .....73 
11.1.  Data Management  ................................ ................................ ................................ .......73 
11.2.  Electronic  Systems  ................................ ................................ ................................ ......73 
12. STUDY MONITORING  ................................ ................................ ............................ 73 
12.1.  Monitoring of Study Sites  ................................ ................................ ........................... 73 
12.2.  Source Document Requirements  ................................ ................................ ................ 73 
12.3.  Case Report Form Requirements  ................................ ................................ ................ 74 
13. AUDITS AND INSPECTIO NS ................................ ................................ ................. 74 
14. ETHICAL AND REGULATO RY CONSIDERATIONS  ................................ .......... 75 
14.1.  Good Clinical Practice Statement  ................................ ................................ ............... 75 
14.2.  Informed Consent  ................................ ................................ ................................ .......75 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406541]/Ethics Committee  ................................ ........................... 76 
14.5.  Clinical Study Data Transparency  ................................ ................................ .............. 76 
15. PROTOCOL AMENDMENTS  ................................ ................................ .................. 76 
16. PREMATURE TERMINATIO N OF THE STUDY OR CL OSE -OUT OF A 
SITE  ................................ ................................ ................................ ............................ 76 
16.1.  Premature Termination of the Study  ................................ ................................ ........... 76 
16.2.  Close -out of a Site  ................................ ................................ ................................ ......76 
17. STUDY DO CUMENTATION  ................................ ................................ ................... 77 
17.1.  Certification of Accuracy of Data  ................................ ................................ ............... 77 
17.2.  Retention of Records  ................................ ................................ ................................ ..77 
18. DATA QUA LITY ASSURANCE  ................................ ................................ .............. 77 
19. CONFIDENTIALITY  ................................ ................................ ................................ 78 
20. FINANCING AND INSURA NCE  ................................ ................................ ............. 78 
21. PUBLIC ATION POLICY  ................................ ................................ .......................... 78 
22. REFERENCES  ................................ ................................ ................................ ........... 79 
23. INVESTIGATOR’S AGREE MENT  ................................ ................................ .......... 82 
SIGNATURE [CONTACT_11715]’S RESPONS IBLE OFFICERS  ................................ ..................... [ADDRESS_406542] OF TABLES  
Table  1: Schedule of Events  ................................ ................................ ................................ .....42 
Table  2: Follow -up Period for Patients Undergoing Joint Replacement Surgery on 
Study  ................................ ................................ ................................ ........................... [ADDRESS_406543] OF FIGURES  
Figure  1: Study Flow Diagram  ................................ ................................ ................................ ...26 
 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406544] of fasinumab 
compared to placebo on peripheral nerves in patients with pain due to 
osteoarthritis (OA) of the hip or knee .  
Secondary Objectives  
The secondary objecti ves of the study are:  
 To evaluate the efficacy of fasinumab compared to placebo in 
patients with pain due to OA of the hip or knee  
 To evaluate the safety and tolerability of fasinumab compared to 
placebo in patients with pain due to OA of the hip or knee  
 To characterize the concentrations of fasinumab in serum in 
patients with pain due to OA of the hip or knee  
 To evaluate the immunogenicity of fasinumab in patients with pain 
due to OA of the hip or knee  
Study Design  This is a phase 2, randomized, double -blind, placebo -controlled, multicenter 
study designed to evaluate the neurological safety of fasinumab compared 
to placebo in patients with pain due to OA of the hip or knee.  In addition, 
the safety, efficacy, pharmacokinetics (PK), and immunogenic ity of 
fasinumab compared to placebo will be assessed.  
The study duration will be approximately 64 weeks starting at 
randomization (day 1). The study consists of a screening period of up to 30 
days, a 7 to 10 day pre -randomization period (7 days with a +3 day window), 
a 16-week treatment period (with the last every 4 week [Q4W] dose of study 
drug administered at week 12), a [ADDRESS_406545] dose of study drug is 
administered.  
Screening  and Pre -Randomization  
Prior to randomization, patients will undergo screening procedures, 
including X -ray of the shoulders, hips, and knees. M agnetic resonance 
imaging (MRI) of the index and contralateral joints must be performed at 
screening and the resu lts assessed by [CONTACT_11343]. In 
addition, an MRI will be performed on any knee or hip joint with a Kellgren -
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 13 of 83 
CONFIDENTIAL  Lawrence (K -L) score of ≥3. Randomization visits cannot occur until there 
is confirmation from the central imaging vendor that there are no 
exclusionary findings on the X -rays and any required MRIs.   
Prior to randomization, patients will also undergo nerve conduction 
assessments.  Patients must complete all other inclusion/exclusion 
assessments before undergoing the nerve conduction assessments.  
Randomization cannot occur until there is confirmation f rom the central 
reader assessment that the results are within the established parameters . 
During the screening period, patients may continue to take their current 
treatment regimen for OA pain .  
Patients eligible for the study will complete a pre -randomiza tion period. The 
pre-randomization visit will be 7  to 10 days before the randomization visit. 
During this period, patients will discontinue and/or undergo a washout of 
their current pain medications for OA.  All pain medication, except for the 
study -provid ed rescue medication (acetaminophen/paracetamol), will be 
discontinued.  
Randomization  
On day 1 (baseline), approximately 180 patients will be randomized in a 1:1 
ratio to fasinumab 1  mg subcutaneous (SC) Q4W or fasinumab -matching 
placebo SC Q4W. Randomizat ion will be stratified according to the affected 
index joint (hip or knee) and the K -L score (2 to 3, or 4) at the screening 
visit.  
Treatment  
During the treatment period (day  1 through week  16), patients will be 
permitted to use only study -provided acetam inophen/paracetamol as rescue 
medication. Patients will record their use of acetaminophen/paracetamol in 
a diary.  
Neurological, efficacy and safety assessments will be performed during the 
treatment period.  
Follow -up 
Follow -up of patients will continue f or an additional [ADDRESS_406546] undergo joint replacement (JR) surgery during the follow -
up period, he or she will be a sked to complete pre -operative imaging and to 
undergo post -surgery follow -up. 
End of study Phone Contact  
A phone contact [CONTACT_329096] [ADDRESS_406547] to JR surgery (if patient underwent, is scheduled for, or is on a 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406548] for JR surgery).  Patients who had an adjudicated arthropathy (AA) 
will have an MRI performed of the affected joint(s).  
Study Duration  The duration of the study  is up to [ADDRESS_406549] patient in 
this study.  
Population   
 Sample Size:  Enrollment of approximately 180 patients is planned for this study 
(approximately 90 patients per treatment group)  
 Target Population:  Men and women who are at least 18 years of age at the time of study entry 
with a clinical diagnosis at the screening visit of OA of the knee or hip, 
based on the American College of Rheumatology criteria, and with 
radiologic evidence of OA (K -L score ≥2) at the index joint.  
Treatments   
 Study Drug  
 Dose/Route/Schedule:  Fasinumab  
1 mg SC Q4W  
 Study Drug Placebo  
 Route/Schedule:  Fasinumab -matching placebo  
SC Q4W  
 Rescue Treatment:  Starting at pre -randomization to the end of the 16 -week treatment period, 
acetaminophen/paracetamol is the only study -provided rescue medication. 
In the event of inadequate pain relief for OA or in the event of other pain 
(eg, headache) or fever, 1 to 2 ta blets/capsules of 
acetaminophen/paracetamol may be taken no less than [ADDRESS_406550] of care.  
Endpoints   
 Primary:  
The primary endpoints of the study are:  
 Change from baseline to week 16 in peroneal motor nerve 
conduction velocity  
 Change from baseline to week 16 in peroneal motor nerve action 
potential amplitude  
 Change from baseline to week 16 in sural sensory nerve conduction 
velocity  
 Change from baseline to week 16 in sural sensory nerve action 
potential amplit ude 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 15 of 83 
CONFIDENTIAL   Change from baseline to week 16 in ulnar sensory nerve 
conduction velocity  
 Change from baseline to week 16 in ulnar sensory nerve action 
potential amplitude  
 Secondary:  The secondary endpoints of the study are:  
 Change from baseline to week 16 in Western Ontario and 
McMaster Universities Osteoarthritis Index  (WOMAC) pain 
subscale score  
 Change from baseline to week 16 in WOMAC physical function 
subscale score  
 Safety:  Additional safety endpoints in this study  include:  
 Incidence of AA (as confirmed  by [CONTACT_329097]) through week 36  
 Incidence of destructive arthropathy (DA) (as confirmed by [CONTACT_329098]) through week 36  
 Incidence of treatment -emergent adverse event (TEAEs) through 
week 16  
 Incidence of sympathetic nervous system (SNS) dysfunction (as 
diagnosed after consultation with an appropriate specialist, such as 
a neurologist and/or cardiologist) through week 36  
 Incidence of peripheral sensory adverse events (AEs) that require 
a neurology or other specialty consultation through week 36  
 Incidence of all -cause JR surgeries through week 36   
 Incidence of JRs at telephone survey approximately [ADDRESS_406551] dose of study drug  
 Pharmacokinetic 
 variable:  The PK variable is the concentration of functional fasinumab in serum 
samples collected at spec ified time points.  
 Anti -drug antibody 
 variables:  Anti-drug antibody (ADA) variables include s tatus (positive or negative), 
titer, and time  point/visit . 
Procedures and Assessments  At the screening v isit, patients will provide informed consent, medical 
history, and medication history.  Determination of the K -L score of the knee 
or hip will be performed to establish a diagnosis of OA based on the 
American College of Rheumatology criteria using a K -L score cutoff of ≥2.  
Patients will be assessed for childbearing potential.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406552] to JR surgery (if p atient underwent, is scheduled for, or is on a wait 
list for JR surgery). Patients who had an AA will have an MRI performed of 
the affected joint(s).  
Statistical Plan  Statistical Hypothesis  
No formal hypothesis testing will be performed on nerve conducti on 
measures. The treatment difference between fasinumab and placebo in the 
change from baseline to week 16 in nerve conduction measures will be 
estimated and presented descriptively along with 95% confidence intervals.  
Justification of Sample Size  
Approxim ately 180 patients will be randomized in a 1:1 ratio to fasinumab 
1 mg Q4W or placebo. With this sample size, the precision of the estimated 
treatment difference between fasinumab and placebo at week 16 in nerve 
conduction velocity is no more than 1.21 m/s  with a 95% confidence level, 
assuming a standard deviation (SD) of 3.6 m/s. This sample size provides 
similar precision for the estimated treatment difference in nerve conduction 
amplitude assuming a SD of 3.6  μV. Assuming a 2 -sided alpha level of 0.05 
and a 15% dropout rate up to week 16, an enrollment of [ADDRESS_406553] 80% power to detect an effect size of 0.46 in the 
WOMAC pain and physical function subscale scores (ie, absolute treatment 
difference of 1.1 between fasinumab and placebo with an SD of 2.4). The 
assumed treatment difference and SD are based on results from study 
R475 -PN-1227.  
Statistical Methods  
For continuous variables, descriptive statistics will include the following 
information:  the number of patients refl ected in the calculation (n), mean, 
median, standard deviation,  minimum, Q1, Q3, and maximum.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406554] (AESIs), vital signs, physical 
exams, laboratory tests, electrocardiograms (ECGs), and ADA formation 
will be listed and summarized by [CONTACT_1570]. The nerve conduction 
variables will be analyzed using a mixed -effect model repeated measure 
(MMRM) approach based on the safety analysis set (SAF). The least -
squares mean estimates for the mean change from baseline to week 16, as 
well as the differences of the estimates between fasinumab and placebo, with 
their corresponding standard errors and associated 95% confidence 
intervals, will be provided descriptively.  
The efficacy variables will be analyzed using multiple imputation approach 
with MMRM based on the full analysis set (FAS) with adjustment for 
missing data due to lack of efficacy or AEs assuming the scores would on 
average return to baseline values.  
For analysis of categorical variables, eg, proportions of patients with ≥30% 
improvement in the WOMAC pain subscale scores at week 16, the Cochran 
Mantel Ha enszel approach stratified by [CONTACT_329099] -response.  
Summaries of serum concentrations of functional fasinumab will be 
presented by [CONTACT_4702]. Plots of individual concentration over time  
will be presented by [CONTACT_73501]. Plots of mean or median concentrations of 
functional fasinumab will be presented by [CONTACT_73502]. No formal statistical 
analysis will be performed.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406555]  Aspartate aminotransferase  
AUC  Area under the curve  
bpm Beats per minute  
CRF  Case report form (electronic or paper)  
CRO  Contract research organization  
CTCAE  Common Terminology Criteria for Adverse Events  
DA Destructive arthropathy  
DMC  Data Monitoring Committee  
EC Ethics Committee  
ECG  Electrocardiogram  
EDC  Electronic data capture  
ESR Erythrocyte sedimentation rate  
FAS Full analysis set  
FDA  Food and Drug Administration  
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HIV Human immunodeficiency virus  
ICF Informed consent form  
ICH International Council for Harmonisation  
INR International normalized ratio  
IRB Institutional Review Board  
IV Intravenous  
IWRS  Interactive web response system  
JR Joint replacement  
K-L Kellgren -Lawrence  
MedDRA  Medical Dictionary for Regulatory Activities  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406556]  Upper limit of normal  
WBC  White blood cell  
WOCBP  Woman of child -bearing potential  
WOMAC  Western Ontario and McMaster Universities Osteoarthritis Index  
 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 20 of 83 
CONFIDENTIAL  1. INTRODUCTION  
Chronic musculoskeletal pain affects a large proportion of the global population. A significant 
cause of chronic musculoskeletal pain is due to osteoarthritis (OA). Osteoarthritis is a progressive, 
chronic disease caused by [CONTACT_329100], which leads to pain in 
the hips, knee s, hands, feet, and spi[INVESTIGATOR_050]. It is characterized by [CONTACT_73436], osteophyte formation at the joint 
margins, thickening of the joint capsule and mild synovitis. Symptoms  and disability increase with 
increasing age. The prevalence of OA in patients aged 65 and older is 60% in men and 70% in 
women, and is continually rising ( Sarzi -Puttini  2005 ). 
Nonsteroidal anti -inflammatory drugs (NSAIDs) are the mainstay of treatment in patients with 
mild-to-moderate OA. The efficacy of NSAIDs is well documented, albeit modest, but their use is 
associated with a number of risks ( Bingham  2007 , Bjordal  2004 , Makarowski  2002 , 
Silverstein  2000 ). The risks associated with long -term therapy with NSAIDs in particular, have 
been well characterized and include gastrointestinal bleeding and increased risk of car diovascular 
events ( Lanas  2011 , Trelle  2011 ). Nonsteroidal anti -inflammatory drugs have limited efficacy in 
many OA patients; those with advanced OA typi[INVESTIGATOR_329073].  
Treatment guidelines for OA suggest that opi[INVESTIGATOR_73385], intolerable, or otherwise contraindicated. However, the use of opi[INVESTIGATOR_329074], nausea and vomiting, constipation, and potential for 
abuse and dependence. In addition, opi[INVESTIGATOR_73387], including drowsiness, dizziness, gastrointestinal intolerability , motor imbalance, 
respi [INVESTIGATOR_2341], and even death. Opi[INVESTIGATOR_329075]. Moreover, there is no evidence to 
support superiority of opi[INVESTIGATOR_329076]. While the efficacy of opi[INVESTIGATOR_73390] a short duration is supported by [CONTACT_73437], long -term efficacy has not been 
evaluated.  
Thus, there remains an unmet medical need for alternative treatment options to opi[INVESTIGATOR_329077] 
a more effectiv e analgesic effect, particularly since there are a significant number of patients who 
are intolerant to or do not get adequate pain relief from the currently available treatment options. 
Inadequate pain relief has a profound impact on the quality of life f or millions of people worldwide 
with an associated substantial cost to society, including healthcare cost ( Salmon  2016 ) and loss of 
productivity ( Dibonaventura  2011 ). 
Neurotrophins are a family of peptide growth factors that play a role in the development, 
differentiation, survival, and death of neuronal and non -neuronal cells (Chao  2006 ). Nerve growth 
factor (NGF) was the first neurotrophin to be identified, and its role in the development and 
survival of both peripheral and central neurons during the development of the nervous system is 
well characterized  (Crowley  1994 , Smeyne  1994 ). In the adult, NGF is not required as a survival 
factor but acts as a pain mediator that sensitizes neurons (Pezet  2006 ). Nerve growth factor activity 
is mediated through 2 different membrane -bound receptors, the high -affinity  tyrosine kinase type 
1 (TrkA) and the low -affinity p75 neurotrophin receptors.  
By [CONTACT_73438], the NGF/TrkA system appears to play 
a major role in the control of pain. Administration of NGF has been shown to provoke pain in both 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 21 of 83 
CONFIDENTIAL  rodents ( Lewin  1994 ) and humans ( McArthur  2000 ), while NGF antagonists have been shown to 
prevent hyperalgesia and allodynia in animal models of neuropathic and chronic inflammatory 
pain ( Ramer  1999 ). Huma ns with mutations in TrkA (hereditary sensory and autonomic 
neuropathy IV) or NGF (hereditary sensory and autonomic neuropathy V) have been identified 
with a loss of deep pain perception ( Einarsdottir  2004 , Indo 1996 ). In addition, NGF is known to 
be elevated in the synovial fluid of patients with rheumatoid arthritis and other types of arthritis 
(Aloe  1992 , Halliday  1998 ), and to be up -regulated in injured and inflamed tissues in conditions 
such as cystitis, prostatitis, and chronic headache ( Lowe  1997 , Miller  2002 , Sarchielli  2001 ). 
Fasinumab (also known as REGN475) is a  fully -human high -affinity monoclonal antibody 
directed against NGF. By [CONTACT_73439], fasinumab has the potential to be effective in 
modulating NGF -associated pain without some of the adverse side effects of other analgesic 
medications, such as  opi[INVESTIGATOR_73392]. Following an evaluation of the safety and tolerability 
of the antibody in a single -ascending -dose first -in-human study (study  R475 -PN-0817), a 
proof -of-concept study evaluating the effect of fasinumab on pain in 217  patients with OA of  the 
knee was completed (study R475 -PN-0901, see current version of the Fasinumab Investigator’s 
Brochure). Three intravenous (IV) doses of fasinumab were evaluated (0.03,  0.1, 0.3  mg/kg every 
8 weeks [Q8W]). All 3 doses, compared with placebo, were associ ated with statistically significant 
improvement in pain as evaluated by [CONTACT_73440], the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC), and the Patient’s Global Impression of Change 
questionnaire. Additionally, another study (R475 -PN-1227) in patients with OA revealed 
significant efficacy in the WOMAC pain subscale score for each of the doses of fasinumab 
evaluated (1 mg, 3 mg, 6  mg, and 9  mg given every 4 weeks [Q4W]) compared with placebo (see 
current version of the Investig ator’s Brochure). Results from recent clinical studies with other anti -
NGF antibodies, tanezumab ([COMPANY_007]) and fulranumab (Janssen), also support the role of NGF in 
pain modulation in patients with pain due to OA of the knee and hip ( Brown  [ADDRESS_406557]  2010 ) and in patients with chronic low back pain ( Katz  2011 , Kivitz  2013 ).  
In all clinical studies completed to date, fasinumab was generally well tolerated. Arthralgia, joint 
swelling, peripheral edema, hypoesthesia, and myalgia were more frequently reported in 
fasinumab -treated patients than in placebo -treated patients. In neur ological evaluations, 
abnormalities in vibration sense were more frequent in the fasinumab patients than in the placebo 
patients. These adverse events (AEs) or physical examination abnormalities associated with 
fasinumab were generally mild to moderate in intensity and were transient (see current version of 
the Investigator’s Brochure).   
Data from studies of tanezumab and fulranumab indicated that these molecules were associated 
with an increased risk of destructive arthropathy (DA), a unique clinical form  of rapi[INVESTIGATOR_73393].  
Analyses of the tanezumab data by [CONTACT_23662], defined by [CONTACT_73441] (JR), revealed th at the risk of DA increases with 
tanezumab dose and is further increased with the concomitant use of chronic NSAIDs (>90  days) 
(Lane  2010 ). Most cases of DA occurred in joints w ith a documented history of OA.  
Based on the potential risk of DA identified in tanezumab and fulranumab, the US Food and Drug 
Administration (FDA) placed the class of anti -NGF antibodies on clinical hold in 2010. Following 
a review of anti -NGF antibody clinical data in March 2012, the FDA determined that clin ical 
studies of anti -NGF therapi[INVESTIGATOR_329078]-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 22 of 83 
CONFIDENTIAL  the risk of DA. To address concerns about  potential events of DA, a risk -mitigation approach is 
also being implemented for all fasinumab studies, as outli ned in Section  [IP_ADDRESS] .  This approach 
includes sensitive, prospective, and rigorous radiologic screening and monitoring for select 
changes in joint  structure. Patients who develop these changes, which are referred to throughout 
this document as adjudicated arthropathy (AA), are required to discontinue study therapy.  
Since the removal of the FDA clinical hold, Regeneron Pharmaceuticals, Inc, (Regener on) has 
conducted or initiated several clinical studies of fasinumab. In all clinical studies to date, 
fasinumab was associated with a low rate of discontinuations due to AEs. Patients treated with 
fasinumab generally had more frequent events than did plac ebo-treated patients of arthralgia, joint 
swelling, peripheral edema, altered peripheral sensation (eg, paresthesia, dysesthesia), and 
myalgia.  
In the phase 2/3 study of fasinumab in patients with pain due to OA of the knee or hip (R475 -PN-
1227), 26 AA eve nts occurred in 24  patients. There was an increase in AA events that appeared to 
be related to greater fasinumab dose. Although these events were milder than the severe DA events 
presented at the 2012 FDA Arthritis Advisory Committee, in consideration of t he lack of an 
observed dose response for efficacy in OA, the risk -benefit ratio was deemed unfavorable for the 
fasinumab 6  mg Q4W and 9  mg Q4W doses in patients with OA in comparison to the other 
fasinumab doses that w ere studied (ie, 1 mg Q4W and 3  mg Q4W ).  The dose regimens that were 
being evaluated in the phase 3 studies for OA pain in the knee or hip included 1 mg Q8W, 
1 mg Q4W, 3 mg Q4W, and 6  mg Q8W.  In April 2018, the independent Data Monitoring 
Committee (DMC) recommend ed discontinuing 6 mg Q8W an d 3 mg Q4W (expected to have 
similar exposure to 6 mg Q8W) based on a review of unblinded data in study R475 -PN-1523.  
Subsequently, a small Regeneron team reviewed the data and agreed with this recommendation.  
The DMC noted imbalances in clinically relev ant AEs including time to total joint replacement, 
peripheral edema, arthralgia and a trend towards early fractures.  The phase [ADDRESS_406558] dose regimen of 1 mg 
Q4W, whi ch is supported by [CONTACT_329101] a favorable benefit -risk profile.  
In 2012, studies of other anti -NGF monoclonal antibodies identified adverse changes in the 
sympathetic nervous system (SNS) of mature animals of several species (rat and non -human 
primate).  These effects included a reversible decrease in neuron volume. To date, no statistically 
significant or consistent effects of fasinumab on the SNS have been detected in animal studies with 
up to 6 months of treatment. Fasinumab has sub -pi[INVESTIGATOR_329079] (0.35pM).  
Fasinumab has little or no affinity for other neurotrophin family members, showing no detectable 
binding to either brain -derived neurotrophic factor (BDNF) or neurotrophin 3 (NT -3). At high 
concentrations, fasinuma b shows low affinity binding to neurotrophin 4 (NT -4) (344nM).  
Fasinumab’s high specificity for NGF could potentially limit its nervous system impact relative to 
other anti -NGF antibodies with less specificity. Some populations of neurons, such as 
proprio ceptive neurons and some visceral neurons, preferentially express TrkC as their 
neurotrophin receptor. The only neurotrophin that can activate TrkC is NT -3, so blocking NT -3 
could compromise the integrity of these populations of neurons. NT -3 appears to ha ve functional 
benefit in adult organisms. For instance, NT -3 has been shown to be neuroprotective for 
proprioceptive neurons using nerve conduction studies in adult rats ( Liu 2011 ). NT -[ADDRESS_406559] constipation i n adult patients, and is therefore thought to play a role in 
bowel motility ( Parkman  2003 ). Based on the potential risk of SNS toxicity associated with other 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 23 of 83 
CONFIDENTIAL  anti-NGF monoclonal antibodies in animal studies, a risk mitigation approach is being 
implemented for all fasinumab studies, as outlined in Section  [IP_ADDRESS] . 
Fasinumab is currently being evaluated in [ADDRESS_406560] -of-care NSAID for moderate -to-severe pain due to OA of the  hip or knee. 
Study R475 -OA-1688 is designed to compare the efficacy and safety of fasinumab to placebo, and 
to a pooled NSAID arm (celecoxib or diclofenac, which are additional standard -of-care NSAIDs 
for moderate -to-severe pain due to OA of the hip or kn ee). 
The phase 2 study described here is designed to evaluate the neurological safety of fasinumab 
compared to placebo on nerve impulse transmission in motor and sensory nerves. Potential SNS 
symptoms will be monitored using the Survey of Autonomic Symptom s and through assessme nts 
of orthostatic hypotension.  
Additional background information on the study drug and development program may be found in 
the current version of the Investigator’s Brochure.  A benefit -risk statement for fasinumab is also 
provided i n the Investigator’s Brochure . 
2. STUDY OBJECTIVES  
2.1. Primary Objective  
The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on 
peripheral nerves in patients with pain due to OA of the hip or knee .  
2.2. Secondary Objectives  
The secondary objectives of the study are:  
 To evaluate the efficacy of fasinumab compared to placebo in patients with pain due to 
OA of the hip or knee  
 To evaluate the safety and tolerability of fasinumab compared to placebo in patients 
with pain due to O A of the hip or knee  
 To characterize the concentrations of fasinumab in serum in patients with pain due to 
OA of the hip or knee  
 To evaluate the immunogenicity of fasinumab in patients with pain due to OA of the 
hip or knee  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406561] 
a history of inadequate pain relief for t heir OA pain from acetaminophen/paracetamol, and a 
history of intolerance to or inadequate pain relief from oral NSAIDS and opi[INVESTIGATOR_2438] (or are unwilling 
to take opi[INVESTIGATOR_2438]) for OA pain management. This study will evaluate the neurological safety of 
fasinumab com pared to placebo in OA patients treated for up to 16 weeks by [CONTACT_329102], ulnar, and sural nerves. This study 
will also provide additional safety, tolerability, efficacy, pharmacokinetic (PK) , and 
immunogenicity data for fasinumab.  
The target study population was chosen because they currently have unmet medical needs with 
respect to unacceptable pain control , in spi[INVESTIGATOR_329080]. The study will be conducted with appropriate eligibility criteria to exclude patients who 
may be at risk for events of joint damage and SNS effects. Furthermore, specific questionnaires  
and physical examinations will be employed to monitor for any events of arthralgia, worsening 
joint pain, altered peripheral sensation, AA, and SNS effects. All patients included in the study 
will have regular study visits and recei ve diagnostic procedure s (ie, X -rays, magnetic resonance 
imaging [MRI]) to evaluate their ongoing OA.  Adverse event monitoring will be ongoing 
throughout the trial.  
The inclusion of a placebo treatment group is important to accurately determine the neurological 
safety, overall  safety, and efficacy of fasinumab and to more accurately estimate the risk of AEs, 
including the adverse events of special interest (AESI) of AA, SNS dysfunction, and altered 
peripheral sensation. Rescue medication (paracetamol/acetaminophen) will be made  available for 
any patient with breakthrough pain. Therefore, the use of a placebo group is justified, as 
placebo -treated patients will not be placed at significant risk. Patients and investigators can choose 
to end participation at any time.  
The patients will be stratified by [CONTACT_73443] (hip or knee) and by [CONTACT_73444] -Lawrence 
(K-L) score (2 to 3, or 4) of the index joint at screening to enable analysis of efficacy and safety. 
The use of a K -L stratification scheme ensures that there is an equa l distribution of patients with 
the most severe OA at baseline across the treatment groups.  
3.1.2.  Rationale for Dose Selection  
In this study, patients will be randomized to receive fixed -dose, subcutaneous (SC) injections of 
[ADDRESS_406562] dose regimen 
(exposure) under evaluation in the fasinumab phase [ADDRESS_406563] a favorable benefit -risk profile in patients with OA pain . 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406564] demography (eg, age, race, weight, height, etc.), 
disease characteristics including medical and surgical history, and medication history for each 
patient.  
4.2. Primary and Secondary Endpoints  
4.2.1.  Primary Endpoints  
The primary endpoints of the study are:  
 Change from baseline to week 16 in peroneal motor nerve conduction velocity  
 Change from baseline to week 16 in peroneal motor nerve action potential amplitude  
 Change from baseline to week 16 in sural sensory nerve conduction velocity  
 Change from baseline to week 16 in sural sensory nerve action potential amplitude  
 Change from baseline to week 16 in ulnar sensory nerve conduction velocity  
 Change from baseline to week 16 in ulnar sensory nerv e action potential amplitude  
4.2.2.  Secondary Endpoints  
The secondary endpoints of the study are:  
 Change from baseline to week 16 in WOMAC pain subscale score  
 Change from baseline to week 16 in WOMAC physical function subscale score  
4.3. Additional Safety Endpoints  
Additional safety endpoints in this study include:  
 Incidence of AA (as confirmed by [CONTACT_329103]) through 
week 36  
 Incidence of DA (as confirmed by [CONTACT_329103]) through 
week 36  
 Incidence of treatment -emergen t adverse event (TEAEs) through week 16  
 Incidence of SNS dysfunction (as diagnosed after consultation with an appropriate 
specialist, such as a neurologist and/or cardiologist) through week 36  
 Incidence of peripheral sensory AEs that require a neurology or  other specialty 
consultation through week 36  
 Incidence of all -cause joint replacement (JR) surgeries week 36  
 Incidence of JRs at telephone survey approximately [ADDRESS_406565] dose of study 
drug 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 26 of 83 
CONFIDENTIAL  4.4. Pharmacokinetic Variables  
The PK variable is the concen tration of functional fasinumab in serum samples collected at each 
time point.  Samples in this study will be collected using a sparse sampling schedule.  These 
sampling time points are specified in Table  1. 
4.5. Anti -Drug Antibody Variables  
Anti-drug antibody (ADA) variables include status (positive or negative ), titer, and time  
point/visit.  Samples in this study will be collected at the visit s specified in  Table  1. 
5. STUDY DESIGN  
5.1. Study Description and Duration  
This is a phase 2, randomized, double -blind, placebo -controlled, multicenter study designed to 
evaluate the neurological safety of fasinumab compared to placebo in patients with pain due to OA 
of the hip or knee.    
The study duration will be approximately 64 weeks starting at randomization (day 1). The study 
consists of a screening perio d of up to 30 days, a 7 - to 10 -day pre -randomization period (7 days 
with a +3 day window), a 16 -week treatment period (with the last Q4W dose of study drug 
administered at week 12), a [ADDRESS_406566] dose of study drug is administered ( Figure  1).  
Figure  1: Study Flow Diagram  
Screening and 
Pre-randomization  Treatment  Follow -up EOS Phone 
Contact  
[CONTACT_73447] [ADDRESS_406567] 
be performed at screening and the results assessed by [CONTACT_11343]. In addition, an 
MRI will be performed on any knee or hip joint with a K -L score of ≥3. Randomization visits 
cannot occur until there is confirmation from the central imaging vendor that there are no 
exclusionary findings on the X -rays and any required MRIs.   
Prior to randomization, patients will also undergo nerve conduction assessments.  Patients must 
complete all other inclusion/exc lusion assessments before undergoing the nerve conduction 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 27 of 83 
CONFIDENTIAL  assessments.  Randomization cannot occur until there is confirmation from the central reader 
assessment that the results are within the established parameters . 
During the screening period, patients may continue to take their current treatment regimen for OA 
pain.  
Patients eligible for the study will complete a pre -randomization period, during which all pain 
medication, except for the study -provided rescue medication (acetaminophen/paracetamol), will  
be discontinued.  The pre -randomization visit will be 7  to 10 days (7 days with a +3 day window) 
before the randomization visit. Patients will discontinue and/or undergo a washout of their current 
pain medications for OA during the pre -randomization perio d. As needed, during this pre -
randomization period, patients may take acetaminophen/paracetamol for pain relief according to 
the regional standard -of-care (see Section  7.2 for details).  Acetaminophen/paracetamol must not 
be taken within 24 hours prior to the randomization visit.  
5.1.2.  Rescreening  
Retesting during the Screening and Pre -Randomization Periods  
An assessment that fails to meet eligibility criteria may be repeated once within the screening or 
pre-randomization period when approved by [CONTACT_329104]: 1) The failure is believed by [CONTACT_269506] a 
condition that  would resolve or could be treated; or 2) A laboratory value that minimally exceeds 
the cut -off value and is not clinically relevant. Only the assessments that did not meet the eligibility 
criteria require repetition, if done within the screening period or  pre-randomization period.  
Patients may not repeat any assessments if they did not meet the WOMAC criteria, if they had 
orthostatic hypotension (defined in Section  [IP_ADDRESS] ), or if the nerve conduction test showed results 
not within the established parameters as per central reader assessment during the screening or 
pre-randomization visit.  
Rescreening after Screen Failure  
Rescreening can be completed for patients who fail to meet the screening visit window 
requirements or who are unable to complete all imaging assessments within the specified screening 
period.   Patients who are rescreened after the pre -randomization window must be declared screen 
failures, be registered in the interactive web response system (IWRS) as a new patient with a new 
identification number, and then repeat all screening procedures, with the exception of imaging 
assessments. Any imaging assessments would need to be repeated only if they were taken more 
than [ADDRESS_406568] 
orthostatic hypotension (defined in Section  [IP_ADDRESS] ), or if the nerve conduction test showed results 
not within the established parameters as per central reader assessment during th e screening or pre -
randomization visit.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 28 of 83 
CONFIDENTIAL  5.1.3.  Randomization  
On day 1 (baseline), approximately 180 patients will be randomized in a 1:1 ratio to the following 
treatment groups:  
 Fasinumab 1  mg SC Q4W  
 Fasinumab -matching placebo SC Q4W  
Patients will receive treatment as descri bed in Section  7.1. Randomization will be stratified 
according to the affected index joint (hip or knee) and the K -L score (2 to 3, or 4) at the scr eening 
visit.  
5.1.4.  Treatment Period  
During the treatment period (day  1 through week  16), patients will be permitted to use only 
study -provided acetaminophen/paracetamol as rescue medication.  Patients will record their use of 
acetaminophen/paracetamol in a dia ry. Patients should discontinue use of acetaminophen/ 
paracetamol at least [ADDRESS_406569] 2 study visits during the follow -up period (week 26 and week 36).  Neurological, 
efficacy and safety assessments will be performed during the follow -up period, as outlined in 
Table  1.  
Patients will be directed not to take concomitant medications that contain NSAIDs (oral or topi[INVESTIGATOR_2855], 
except up to 150 mg/day of aspi[INVESTIGATOR_248], which is permitted for cardiac prophylaxis) until at least 
[ADDRESS_406570] to JR surgery (if  patient underwent, 
is scheduled for, or is on a wait list for JR surgery). Additionally, patients who had an AA 
confirmed during the study will have an MRI performed of the AA joint(s). If the AA joint(s) have 
undergone JR, an X -ray may be substituted for  an MRI.  
5.1.7.  Study Stoppi[INVESTIGATOR_73399] (DMC) will monitor unblinded data on an ongoing 
basis to assess the risk/benefit profile of fasinumab. Based on these reviews, in the context of the 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 29 of 83 
CONFIDENTIAL  totality of evidence, if the DMC ha s significant concerns at any time regarding a meaningful 
imbalance between treatment groups in joint -related AEs, SNS dysfunction, neurosensory 
disturbances, or any other safety issues, the DMC may make a recommendation to temporarily 
halt, alter, or term inate:  
 individual dose groups within the study or across studies  
 the full study (screening, randomization, dosing of study drug)  
 the fasinumab program  
for additional review and communication to regulatory authorities.  Based on the outcome of the 
review and discussions with the appropriate regulatory authorities, the study may be suspended, 
restarted, or terminated.  
Formal program wide statistical study stoppi[INVESTIGATOR_329081], DMC and/or Health 
Authorities.  
5.1.8.  End of Study Definition  
The end of study is defined as the last phone contact [CONTACT_73453].  
5.2. Planned Interim Analysis  
An interim analysis may be performed in order to provide peripheral nerve safety data for 
regulatory purposes.  
5.3. Study Committees  
5.3.1.  Independent Data Monitoring Committee  
An indepe ndent DMC will meet periodically to review unblinded data as the study progresses, and 
based on the findings, will make recommendations to the sponsors about the conduct of the study. 
The DMC will comprise independent statistical and medical experts. Furth er details will be defined 
in the DMC charter. Additional safety monitoring will occur on an ongoing basis by [CONTACT_73454].  
5.3.2.  Arthropathy Adjudication Committee  
An independent, expert, blinded adjudication committee composed of radiologists trai ned in 
musculoskeletal imaging will adjudicate all potential joint AEs of AA (defined in Section  [IP_ADDRESS] ) 
as well as pre -operative images in patient s undergoing JR.   
6. SELECTION, WITHDRAWA L, AND REPLACEMENT O F 
PATIENTS  
6.1. Number of Patients Planned  
The study will enroll approximately 180 patients at about 30 global sites. Each treatment group 
(fasinumab and fasinumab -matching placebo) will enroll approxim ately 90 patients.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406571] 18 years of age at the 
time of study entry with a clinical diagnosis at the screening visit of OA of the knee or hip, based 
on the American Col lege of Rheumatology criteria, and with radiologic evidence of OA (K -L score 
≥2) at the index joint.  
6.2.1.  Inclusion Criteria  
A patient  must meet the following criteria to be eligible for inclusion in the study:  
1. Male and female patients  ≥18 years of age at screening visit  
2. Provide signed informed consent signed by [CONTACT_173866]  
3. Body mass index ≤39 at screening visit  
4. A clinical diagnosis of OA of the knee or hip based on the American College of 
Rheumatology  criteria with radiologic evidence of OA (K -L score ≥2 for the index joint) 
at the screening visit, with the following definitions:  
 The index joint is defined as the joint with OA under evaluation for this study  
 A joint previously treated with JR surgery c annot be the index joint  
 A joint previously surgically modified within the past year cannot be the index joint 
(with the exception of cruciate ligament reconstruction surgery, patellar fracture repair 
surgery, or meniscal repair)  
 If a patient has a K -L sco re of ≥[ADDRESS_406572] WOMAC pain subscore at the screening visit  
 If [ADDRESS_406573] a K -L score of ≥2 and the same WOMAC pain 
subscore, the index joint is the joint with the greater K -L score  
 If [ADDRESS_406574] a K -L score of ≥2, the same WOMAC pain subscores, and the 
same K -L scores, then the investigator may choose 1 of these joints as the index joint  
5. Moderate -to-severe pain in the index joint defined as a WOMAC av erage pain subscale 
score of ≥4 at both the screening and randomization visits  
6. Willing to discontinue current pain medications and to adhere to study requirements for 
rescue treatments (paracetamol/acetaminophen to be taken as needed with a  maximum 
daily d ose of 2500 mg [countries where 500 mg strength tablets/capsules are available] or 
2600  mg [countries where 325 mg strength tablets/capsules are available])   
7. A history of at least 12 weeks of analgesics use for pain due to OA of the knee or hip, as 
defined  by: 
a. Inadequate pain relief from acetaminophen/paracetamol  AND  
b. Intolerance to or inadequate pain relief from at least 1 oral NSAID AND  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 31 of 83 
CONFIDENTIAL  c. Intolerance to or inadequate pain relief from opi[INVESTIGATOR_73401], unwillingness 
to take opi[INVESTIGATOR_329082] y for a medically acceptable reason, or lack of access 
to an opi[INVESTIGATOR_73403]  
8. A history of regular use of analgesic medications for OA pain (defined as an average of 4 
days per week over the 4 weeks prior to the screening visit), including oral NSAID s, 
selective cyclooxygenase 2 inhibitors, opi[INVESTIGATOR_2438], paracetamol/acetaminophen, or 
combinations thereof  
9. Consent to allow all radiographs and medical/surgical/hospi[INVESTIGATOR_329083]  
10. Willing to maintain current activity and exercise levels throughout the study  
11. Willing and able to comply with clinic visits and study -related procedures  and willing to 
provide follow -up information related to any JR surgery that occu rs within the period of 
time covered by [CONTACT_73455]  
12. Able to understand and complete study -related questionnaires  
6.2.2.  Exclusion Criteria  
A patient  who meets any of the following criteria will be excluded from the study:  
1. History or presence at the screening visit of non -OA inflammatory joint disease (eg, 
rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudo -gout, gout, 
spondyloarthropathy, polymyalgia rheumatica,  joint infections within the past 5 years ), 
Paget's disease of the spi[INVESTIGATOR_050], pelvis or femur, neuropathic disorders, multiple sclerosis, 
fibromyalgia, tumors or infections of the spi[INVESTIGATOR_1831], or renal osteodystrophy  
2. History or presence on imaging of arthropathy (osteonecrosis, subchondral insufficiency  
fracture, rapi[INVESTIGATOR_73405] 1 or type 2), stress fracture, recent stress fracture, 
neuropathic joint arthropathy, hip dislocation (prosthetic hip dislocation is eligible), knee 
dislocation (patella dislocation is eligible), congenital hip dyspla sia with degenerative joint 
disease, extensive subchondral cysts, evidence of bone fragmentation or collapse, or 
primary metastatic tumor with the exception of chondromas or pathologic fractures during 
the screening period  
3. Trauma to the index joint within 3 months prior to the screening visit  
4. History or presence of signs or symptoms of compression neuropathy, including car pal 
tunnel syndrome or sciatica  
5. Patient is not a candidate for MRI  
6. Is scheduled for a JR surgery to be performed during the study period  or who would be 
unwilling or unable to undergo JR surgery if one eventually became necessary  
7. Patients with nerve conduction results (for the peroneal, sural , and ulnar nerves) that are 
outside of the established parameters , based on standards detailed in the study manual and 
according to the eligibility report provide d by [CONTACT_329105]-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 32 of 83 
CONFIDENTIAL  8. Patients receiving, or who plan to receive, interventions, devices, or medications that alter 
nerve conduction or are contraindicated in  patients undergoing nerve conduction studies 
(eg, edema, tarsal tunnel syndrome)  
9. History or presence at the screening visit of autonomic neuropathy, diabetic neuropathy, or 
other peripheral neuropathy, including reflex sympathetic dystrophy and complex re gional 
pain syndrome  
10. History or diagnosis of chronic autonomic failure syndrome including pure autonomic 
failure, multiple system atrophy (Shy -Drager syndrome)  
11. Known allergy or sensitivity to monoclonal antibodies  
12. Poorly controlled diabetes (defined as any  single value of hemoglobin A1c [HbA1c] 
>9.0%) at the screening visit  
13. Known history of human immunodeficiency virus (HIV) infection  
14. Known history of ocular herpes simplex virus, herpes simplex virus pneumonia, or herpes 
simplex virus encephalitis  
15. History o f sickle cell disease, including sickle cell anemia and β -thalassemia  
16. Confirmed elevated screening alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) ≥2.5 times the upper limit of normal (ULN)  
17. Resting heart rate of <50 beats per minute (bpm ) or >100 bpm (by [CONTACT_329106] [ECG] assessment) at the screening or randomization 
visits  
18. History or presence of 2nd or 3rd degree heart block, 1st degree heart block with abnormal 
QRS complex, or bifascicul ar block by [CONTACT_73457]  
19. History or presence of orthostatic hypotension, as defined in Section  [IP_ADDRESS] , at the 
screening, pre-randomization, or randomization visits  
20. History of poorly controlled hypertension, as defined by:  
a. Systolic blood pressure ≥180  mm Hg or diastolic blood pressure ≥110  mm Hg at the 
screening visit  
b. Systolic blood pressure of 160 mm  Hg to 179 mm Hg or dia stolic blood pressure of 
100 mm Hg to 109 mm Hg at the screening visit, AND a history of end -organ damage 
(including history of left ventricular hypertrophy, heart failure, angina, myocardial 
infraction, stroke, transient ischemic attack, peripheral arteri al disease and moderate to 
advanced retinopathy [hemorrhages or exudates, papi[INVESTIGATOR_044]])  
21. Congestive heart failure with [LOCATION_001] Heart Classification of stage III or IV 
(Dolgin  1994 ) 
22. Transient ischemic attack or cerebrovascular accident within the past [ADDRESS_406575] 
6 months prior to the screening visit  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406576] the patient’s participation in the study  
24. New major illness diagnosed within [ADDRESS_406577] been treated successfully with no recurrence for >1  year of basal cell or 
squamous cell carcinoma of the skin or in -situ cervical cancer  
28. History of hospi[INVESTIGATOR_329084] 5 years or active , 
severe major depression at screening  
29. Use of systemic (ie, oral or intramuscular) corticosteroid within 30 days prior to the 
screening visit. Intra -articular corticosteroids in the index joint within 12  weeks prior to 
the screening visit, or to any other joint within 30 days prior to the screening visit (topi[INVESTIGATOR_2855], 
intra-nasal, and inhaled corticosteroids are permitted)  
30. Use of a monoamine reuptake inhibitor, tricyclic antidepressants, selective serotonin 
reuptake inhibito rs and serotonin norepi[INVESTIGATOR_329085] [ADDRESS_406578] results during screening (eg, 
amphetamines/methamphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, coc aine, 
and opi[INVESTIGATOR_858]), unless in the opi[INVESTIGATOR_871], the positive test results may be due 
to the patient’s current permitted medicat ions 
32. History of (within 5 years prior to the screening visit) or current alcoholism, alcohol abuse, 
substance abus e, or abuse of prescription pain medication  
33. History of cannabis use for the treatment of pain within the past [ADDRESS_406579] within 30 days or 5 half -lives of the 
screening visit, whichever is longer  
35. Exposure to an anti -NGF antibody prior to the screening visit or known sensitivity or 
intolerance to anti -NGF antibodies or participation in a cli nical trial evaluating anti -NGF 
antibodies  
36. Member of the clinical site study team and/or his/her immediate family, unless prior 
approval granted by [CONTACT_456]  
37. Pregnant or breastfeeding women  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406580] result at baseline  
39. Women of childbearing potential* who are unwilling to practice highly effective 
contraception prior to start of the first treatment, during the study, and for at least [ADDRESS_406581]  dose.  Highly effective  contraceptive measures include:  
a. stable use of combined (estrogen and progestogen containing) hormonal contraception 
(oral, intravaginal, transdermal) or progestogen -only hormonal contraception (oral, 
injectable, implantable) associ ated with inhibition of ovulation initiated 2 or more 
menstrual cycles prior to screening  
b. intrauterine device (IUD); intrauterine hormone -releasing system (IUS)  
c. bilateral tubal ligation  
d. vasectomized partner  
e. and or sexual abstinence†‡ 
* Postmenopausal w omen must be amenorrheic for at least 12 months (without an alternative 
medical cause) in order not to be considered of childbearing potential.  Pregnancy testing 
and contraception are not required for women with documented  complete  hysterectomy or 
tubal ligation.  
† Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatments.  The reliability of sexual absti nence needs to be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the subject.  
‡ Periodic abstinence (calendar, symptothermal, and post -ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not 
acceptable methods of contraception.  Female condom and male condom should not be 
used together.  
Note: HIV and/or hepatitis testing will be performed on a country -by-country basis, according to 
local gu idelines if required by [CONTACT_25035].  
6.3. Premature Withdrawal from the Study  
A patient has the right to withdraw from the study at any time, for any reason, and without 
repercussion.  
The investigator and/or sponsor have the right to  withdraw a patient from the study if it is no longer 
in the interest of the patient to continue in the study, or if the patient’s continuation in the study 
places the scientific outcome of the study at risk (eg, if a patient does not or cannot follow stud y 
procedures). An excessive rate of withdrawals would render the study uninterpretable; therefore, 
unnecessary withdrawal of patients should be avoided.  
Patients who are withdrawn prematurely from the study will be asked to complete the early 
termination visit, as described in Section  8.1.3 . 
Rules for discontinuation of study treatment (permanent or temporary) are discussed in 
Section  7.3.2 .  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406582] is supplied for this study in the following concentrations:  
 Fasinumab 2 mg/mL:  Each 1 mL single -use pre -filled syringe delivers 0.5 mL of 
2 mg/mL solution to provide a 1 mg dose of study drug  
 Fasinumab -matching placebo:  Each 1 mL single use pre -filled syringe delivers 0.5  mL 
of placebo solution.  
All patients will receive SC injections of fasinumab or fasinumab -matching placebo. Patients will 
be randomized to 2 treatment groups in a 1:[ADDRESS_406583] be given within ±7 days from the scheduled dose date. If the window is 
missed, the dose should not be administered. The next dose should be administered at the  next 
scheduled dosing date.  
7.2. Rescue Treatment  
Starting at pre -randomization to the end of the 16 -week treatment period, study -provided 
acetaminophen/paracetamol is the only allowed rescue medication. In the event of inadequate pain 
relief for OA or in th e event of other pain (eg, headache) or fever, 1 to 2 tablets/capsules of 
study -provided acetaminophen/paracetamol may be taken no less than [ADDRESS_406584] of care. The maximum allowed daily dose during the treatmen t and 
follow up periods is 2500 mg (500 mg x 5 tablets/capsules) in countries where 500 mg strength 
tablets/capsules are available or 2600 mg (325 mg x 8 tablets/capsules) in countries where 325 mg 
strength tablets/capsules are available  (eg, North America ). Where 500  mg strength 
tablets/capsules are available, the highest individual single dose is 1 gram. Where 325  mg 
tablets/capsules are available, the highest individual single dose is 650 mg.  
In order to prevent severe liver damage, patients should be c autioned to avoid consumption of 
alcoholic beverages while on paracetamol/acetaminophen. Patients should also be cautioned not 
to take rescue medication at intervals of fewer than 4 hours and to take no more than the maximum 
allowable single dose (1 to 2 t ablets/capsules) or maximum allowable total daily dose.  
Acetaminophen/paracetamol must not be taken within 24 hours prior to scheduled study visits 
during the treatment period in order to minimize the confounding effects of rescue medication on 
efficacy a ssessment measures. Use of acetaminophen/paracetamol as study -provided rescue 
medication during the treatment period will be reported daily using diaries. 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 36 of 83 
CONFIDENTIAL  Acetaminophen/paracetamol accountability will be conducted at each study site visit starting at 
the b aseline visit and continuing through the week  16 visit.  
During the treatment period, acetaminophen/paracetamol will be sourced by [CONTACT_329107] -specific regulations and customs require a different 
approach.  
During the 20 -week follow -up period, if acetaminophen/paracetamol is used, dosing instructions 
will be the same as during the treatment period including the maximum allowed daily dose. Use 
of acetaminophen/paracetamol will be captured as a concomitant medic ation during the follow -up 
period.  
7.3. Dose Modification and Study Treatment Discontinuation Rules  
7.3.1.  Dose Modification  
Study drug dose modification for an individual patient  is not allowed.  
7.3.2.  Study Drug Discontinuation  
Study drug may be temporarily or permanently  discontinued due to medical need, as determined 
by [CONTACT_093], medical monitor, or the sponsor and according to the study stoppi[INVESTIGATOR_004] 
(Section  5.1.7 ).  
Patient s who permanently discontinue from study drug will be encouraged to remain in the study 
and to complete all study assessments. Patients who agree and thus do not withdraw from the study  
will be asked to return to the clinic for all rem aining study visits per Table  1. 
Patient s who permanently discontinue from study drug and who opt to withdraw from the study 
will be asked to complete an early termination visit (Section  8.1.3 ). 
Patients who discontinue from study drug prior to study completion due to an AA (see 
Section  [IP_ADDRESS] ) should return to the clinic for all remaining study visits per the visit schedule.  
In the event that a patient must undergo JR surgery during the treatment or follow -up periods, 
he/she will be discontinued from study drug a nd asked to return to the study site for a pre -operative 
visit and for follow -up safety evaluations 4 and 20  weeks after surgery (as described in 
Section  [IP_ADDRESS] ). Pre -operative imaging (X -rays and/or MRI) will be obtained and submitted to the 
independent adjudication committee for review to exclude or confirm the presence of an AA event. 
Instructions for the submission process are provided in the stud y manual.  
[IP_ADDRESS].  Reasons for Permanent Discontinuation of Study Drug  
Study drug dosing will be permanently stopped in the event of: 
 A patient developi[INVESTIGATOR_73407] a neurologist’s examination  and graded by [CONTACT_329108],  ie, grade ≥2 
according to Common Terminology Criteria for Adverse Events (CTCAE) v.4; study 
sites should use CTCAE v.[ADDRESS_406585] udy for consistency  
 Evidence of pregnancy  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 37 of 83 
CONFIDENTIAL   A patient developi[INVESTIGATOR_329086]  
 Continued noncompliance with protocol -defined maximum acetaminophen/ 
paracetamol use (with a maximum daily dose of 2500  mg [countries where 500  mg 
strength tablets/capsules are available] or 2600  mg [countries where 325  mg strength 
tablets/capsules are available]) during the treatment and follow -up periods, after 
appropriate counseling  
 Continued noncompliance with the protocol, including  usage of NSAIDs or other 
medications or non -pharmacologic treatments that are not permitted in the study, after 
appropriate counseling  
 JR surgery  
 AESI:  
 Adjudicated arthropathy, as described in Section  [IP_ADDRESS] . 
 Sympathetic nervous system dysfunction , as described in Section  [IP_ADDRESS].  
 Per protocol repeat ed nerve conduction test that confirms results are not within the 
established parameters for peroneal, sural , or ulnar nerves, as per central reader 
assessment  and the neurologist’ s evaluation that confirms the diagnosis of peripheral 
neuropathy . 
 Hepatotoxicity.  Study drug should be discontinued if the following are observed:  
1. Total bilirubin  (TBL) >2x ULN or international normalized ratio (INR) >1.5, and  
2. ALT or AST >3x  ULN, and  
3. No other cause for 1 and 2 is readily apparent  
Other causes of ALT, AS T, and TBL elevations may include alcoholic hepatitis, 
autoimmune hepatitis, non -alcoholic hepatitis, heritable diseases (Gilbert's Syndrome), 
heart  failure, and viral hepatitis.  
NOTE: Study drug may be withheld in patients who do not meet criteria for permanently 
discontinuing study drug, until an alternative cause for drug -induced liver injury can be 
determined. The patient may be re -challenged if an alternative cause for elevated liver 
function tests is found and the liver function tests return to bas eline, but only after 
discussion with the sponsor.  
 Systemic hypersensitivity reaction deemed by [CONTACT_7281] 
 Any other medical need, as determined by [CONTACT_093]  
 Sponsor decision  
 Patient withdraws consent  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 38 of 83 
CONFIDENTIAL  [IP_ADDRESS].  Reasons for Te mporary Discontinuation of Study Drug  
Study drug may be temporarily discontinued due to medical need, as determined by [CONTACT_1275]. Study drug will be temporarily withheld while awaiting imaging adjudication for 
worsening joint pain or when routine im aging suggests AA and prompts the need for additional 
imaging (see Section  [IP_ADDRESS] ), for patients who are determined to have orthostatic hypotension  or 
determined to have new or worsening symptoms suggestive of SNS dysfunction while awaiting 
evaluation by a specialist (see Section  [IP_ADDRESS] ), or for patients with symptoms of peripheral 
neuropathy while awaiting evaluation by a specialist and/or results of a nerve conduction test (see 
Section  [IP_ADDRESS] ).  
Study drug should not be re -started until the next study visit, unless imaging , nerve conduction 
test results , or neurology evaluation results are available within the current visit window and 
confirm that study drug may be restarted.   
7.4. Manageme nt of Acute Reactions  
7.4.1.  Systemic Injection Reactions  
Emergency equipment and medication for the treatment of systemic reactions must be available 
for immediate use. All systemic injection reactions must be reported as AEs (as defined in 
Section  9.3.1 ) and graded using the grading scales as instructed in Section  9.5.[ADDRESS_406586] be reported as AEs and graded according to Section  9.5.1 . 
7.5. Method of Treatment Assignment  
Approximately 180 patients will be randomized in a 1:1 ratio to receive fasinumab (1  mg SC 
Q4W) or fasinumab -matching placebo (Q4W) according to a central ran domization scheme 
provided by [CONTACT_329109] (or qualified designee). Randomization 
will be stratified according to the affected index joint (hip or knee) and the K -L score (2 to 3, or 
4) at the screening visit.  
7.5.1.  Blinding  
Study patients, the principal investigators, and study site personnel will remain blinded to all 
randomization assignments throughout the study. The Regeneron study team and contract research 
organization (CRO) personnel who are in regular contact [CONTACT_329110].  
Blinded study drug kits coded with a drug numbering system will be used.  In order to maintain 
the blind, lists linking these codes with product lot numbers will not be accessible to indiv iduals 
involved in study conduct.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406587] access to unblinded data before the database is locked for this study.  
7.5.2.  Emergency Unblinding  
Unblinding of treatment assignment for a patient may be necessary due to a medical emergency or 
any other significant medical event (eg,  pregnancy).  
If unblinding is required:  
 Only th e investigator will make the decision to unblind the treatment assignment  
 Only the affected patients will be unblinded  
 The designated study pharmacist(s)/designee at the study site will provide the treatment 
assignment to the investigator. If there is no  study pharmacist, the investigator for the 
site will unblind the patient  
 The investigator will notify Regeneron and/or designee as soon as possible after 
unblinding the patient  
Treatment assignment is not to be provided to site personnel, other than the u nblinded study 
pharmacist (when applicable), at any time during the conduct of the study, except in the case of a 
true emergency.  In the event that there is no study pharmacist, the individual at the site fulfilling 
that role will be the only unblinded me mber of the site personnel.  
7.5.3.  Unblinding for Regulatory Reporting Purposes  
Treatment assignments for certain patients may be unblinded to Pharmacovigilance and Risk 
Management personnel for the purpose of regulatory reporting of Suspected Unexpected Serious 
Adverse Reactions (S[LOCATION_003]Rs).  
7.6. Treatment Logistics and Accountability  
7.6.1.  Packaging, Labeling, and Storage  
A medication numbering system will be used to label blinded investigational study drug. Lists 
linking medication numbers with product lot numbers will be m aintained by [CONTACT_25006] (or 
companies) responsible for study drug packaging. In order to maintain the blind, these lists will 
not be accessible to individuals involved in study conduct.  
Study drug will be stored at the site at a temperature of 2ºC to 8ºC. Storage instructions will be 
provided in the pharmacy manual.  
7.6.2.  Supply and Disposition of Treatments  
Study drug will be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study. At specified time points during the study (eg, interim site 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 40 of 83 
CONFIDENTIAL  monitoring visits), at the site close -out visit, and following drug reconciliation and documentation 
by [CONTACT_25007], all used drug will be destroyed at site while unused drug will be returned to 
the spons or or designee. Refer to pharmacy manual for details.  
7.6.3.  Treatment Accountability  
All drug accountability records must be kept current.  
The investigator must be able to account for all used and unused study drug. These records should 
contain the dates, quanti ty, and study drug that is:  
 dispensed to each patient,  
 returned from each patient (if applicable),  
 disposed of at the site, or returned to the sponsor or designee.  
All accountability records must be made available for inspection by [CONTACT_329111]; photocopi[INVESTIGATOR_24897].  
7.6.4.  Treatment Compliance  
All study drug compliance records must be kept current and made available for inspection by [CONTACT_28790] . 
7.7. Concomitant Medications and Procedures  
Any treatment administered and/or procedures performed from screening  to the end of the follow -
up period will be considered concomitant medication and/or procedures, respectively.  This 
includes medications and/or p rocedures that were started before the study and are ongoing during 
the study.  
7.7.1.  Prohibited Medications  
Patients will be required to discontinue all non -study pain medication (oral or topi[INVESTIGATOR_2855]; except up 
to 150 mg/day of aspi[INVESTIGATOR_248]/aminosalicylic acid [5 -ASA], which is permitted for cardiac prophylaxis, 
per local guidelines ), starting at the pre -randomization visit and through the treatment period.  
Opi[INVESTIGATOR_73409] (including tramadol) are prohibited thr ough the week  16 study visit.  
Patients will be directed not to take concomitant medications that contain NSAIDs (oral or topi[INVESTIGATOR_2855], 
except up to 150 mg/day of aspi[INVESTIGATOR_248], which is permitted for cardiac prophylaxis) until at least 
[ADDRESS_406588] given to patients.  
Other excluded medications during the treatment period include:  
 Any other investigational agent  
 Medical or regular recreational use of marijuana  
 Chondroitin sulfate  
 Glucosamine   
 Hyaluronic Acid Intra -articular Injections  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 41 of 83 
CONFIDENTIAL   Muscle relaxants including cyclobenzaprine, carisoprodol, orphenadrine, tizanidine 
(see Section  7.7.2  for permitted muscle relaxants)  
 Corticosteroids (topi[INVESTIGATOR_2855], intranasal, and inhaled formulations are permitted ), 
adrenocorticotropic hormone  
 Cyclosporine , methotrexate, mycophenolate mofe til, tacrolimus  
 Azathioprine , sulfasalazine, hydroxychloroquine  
 IL-6 or IL -6 receptor antagonists  
 Abatacept , ustekinumab  
 Tumor necrosis factor antagonists  
 IL-1 inhibitors, including diacerein  
 Apremilast, and tofacitinib  
7.7.2.  Permitted Medications and Procedu res  
Patients receiving chronic medication therapy must be on a stable dose of such medication for at 
least the [ADDRESS_406589] 4  weeks prior to the screening visit and 
throughout the planned duration  of the patient’s participation in the study.  
Low-dose aspi[INVESTIGATOR_248]/5 -ASA (up to 150 mg/day) for cardiac prophylaxis is permitted. 
Acetaminophen/paracetamol taken acutely for treatment of non -OA pain is permitted, however, 
the total daily dosage limits cannot b e exceeded regardless of the reason for 
acetaminophen/paracetamol use.  During the pre -randomization and treatment periods, 
acetaminophen/paracetamol use will be captured in the diary; use for relief of pain other than pain 
due to OA w ill be reported in th e diary as "other".  During the screening and follow -up periods, 
acetaminophen/paracetamol taken for any reason should be reported as concomitant medication. 
Topi[INVESTIGATOR_12977].  
Muscle relaxants, such as Skelaxin® (metaxalone) and others, are permitted.  Prohibited muscle 
relaxants are listed in Section  7.7.1 .  
Physical therapi[INVESTIGATOR_014] (such as transcutaneous electrical nerve stimulation and acupuncture) are 
permitted during the trial, provided that patients have been on a stable regimen for at least [ADDRESS_406590] to maintain this regimen during the trial.  
Joint replacement is a permitted procedure during the study (see Section  [IP_ADDRESS]  for procedures to 
be followed in the event of JR).  
8. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  
8.1. Schedule of Events  
Study assessments and procedures are presented by [CONTACT_25010]  1. 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 42 of 83 
CONFIDENTIAL  Table  1: Schedule of Events  
 Screening/Pre -
randomization  Treatment Period  Follow -up Period  EOS  
Study Week  Screen  Pre-
rand   
Baseline   
Wk 1   
Wk 2   
Wk 4   
Wk 8   
Wk 12  EOT  
Wk 16  ET1/ 
JR 
Pre-
Op   
Wk 26   
Wk 36  ET1 
/JR 
Pre-
Op  
Wk 64  
Study Day  Up to 30 
Days  7 to 10 
Days  1 8 15 29 57 85 113 183 253 449 
Visit Window (days)     ±1 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 
Visit/ Phone Contact 
[CONTACT_329112] 1  Visit 2  Visit 3  Visit  4 Visit 5  Visit 6  Visit 7  Visit 8  Visit 9  Visit 10  Visit 11  Phone 
1 
Screening/Baseline:                
Inclusion/Exclusion2 X X X            
Main study informed 
consent  X              
Genomics sub -study 
informed consent3 X              
Medical history  X              
Medication history  X              
Demographics X              
Diary instructions   X X            
Training on pain 
reporting /patient 
education brochures 4 X X             
MRI for index joint, 
contralateral joint & any 
hip or knee with K -L ≥3 X              
Randomization    X            
Treatment:                
Discontinue non -study 
pain medications   X             
Study drug SC injection5   X   X X X       
Dispense to home 
paracetamol/ 
acetaminophen   X X   X X X       
Paracetamol/ 
acetaminophen 
accountability    X  X X X X X X     
Record rescue 
medication use in diary6  X X X X X X X X X     
Concomitant therapi[INVESTIGATOR_014]  X X X X X X X X X X X X X  
Patient -Completed Assessments/Efficacy:              
WOMAC7, 22 X7  X  X X X X X X X X X  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 43 of 83 
CONFIDENTIAL   Screening/Pre -
randomization  Treatment Period  Follow -up Period  EOS  
Study Week  Screen  Pre-
rand   
Baseline   
Wk 1   
Wk 2   
Wk 4   
Wk 8   
Wk 12  EOT  
Wk 16  ET1/ 
JR 
Pre-
Op   
Wk 26   
Wk 36  ET1 
/JR 
Pre-
Op  
Wk 64  
Study Day  Up to 30 
Days  7 to 10 
Days  1 8 15 29 57 85 113 183 253 449 
Visit Window (days)     ±1 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 
Visit/ Phone Contact 
[CONTACT_329112] 1  Visit 2  Visit 3  Visit  4 Visit 5  Visit 6  Visit 7  Visit 8  Visit 9  Visit 10  Visit 11  Phone 
1 
Neurological 
Assessments:                
Nerve conduction  X8      X  X X9  X X9  
Neurological 
examination (full)  X  X  X X X X X X X X X  
Survey of autonomic 
symptoms22 X  X  X X X X X X X X X  
Orthostatic blood 
pressure assessment and 
heart rate 10,11  X X X  X X X X X X X X X  
Safety:                
Vital signs11 X  X  X X X X X X X X X   
Electrocardiogram  X        X X     
Physical examination 
and weight  X        X X  X X  
Joint pain questionnaire22  X  X  X X X X X X X X X  
Event -triggered 
imaging12    X X X X X X X X X X  
Adverse Events  ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------   
SC injection site 
evaluation    X   X X X       
Bilateral X -rays (knee, 
hip, shoulder)  X13        X X  X X  
Pre-op questionnaire (JR 
follow -up)14    
       X   X  
MRI affected joint(s) - 
AA patients only15              X 
End of study phone 
contact16              X 
Laboratory Testing:                
Urine drug test17 X              
Hematology17 X     X  X X X X X X  
Blood chemistry17 X     X  X X X X X X  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 44 of 83 
CONFIDENTIAL   Screening/Pre -
randomization  Treatment Period  Follow -up Period  EOS  
Study Week  Screen  Pre-
rand   
Baseline   
Wk 1   
Wk 2   
Wk 4   
Wk 8   
Wk 12  EOT  
Wk 16  ET1/ 
JR 
Pre-
Op   
Wk 26   
Wk 36  ET1 
/JR 
Pre-
Op  
Wk 64  
Study Day  Up to 30 
Days  7 to 10 
Days  1 8 15 29 57 85 113 183 253 449 
Visit Window (days)     ±1 ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 
Visit/ Phone Contact 
[CONTACT_329112] [ADDRESS_406591] (for 
WOCBP)19 X - 
Serum   X - 
Urine    X - 
Urine  X - 
Urine  X - 
Urine  X - 
Urine  X – 
Urine  X - 
Urine  X – 
Urine  X – 
Urine   
PK, Antibody, and Research Samples:              
PK sample20   X X X X X X X X  X X  
ADA samples20   X      X X  X X  
Genomics sub -study 
sample (optional)3   X            
hs-CRP sample20,21   X   X   X X  X X  
Research serum/plasma 
sample20,21    X   X   X X  X X  
AA: Adjudicated arthropathy  JR: Joint replacement  
ADA: Anti -drug antibody  MRI: Magnetic resonance imaging  
EOS: End of study  PK: Pharmacokinetic  
EOT: End of treatment  Pre-op: Pre -operative  
ESR: Erythrocyte sedimentation rate  Pre-rand: Pre -randomization  
ET: Early termination  SC: Subcutaneous  
FSH: Follicle stimulating hormone  Wk: Week  
HbA1c: Glycated hemoglobin  WOCBP: Women of childbearing potential  
hs-CRP: high -sensitivity C -reactive Protein  WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index  
  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 45 of 83 
CONFIDENTIAL  8.1.1.  Footnotes for the Schedule of Events Table 1  
1. Patients who discontinue study drug will be encouraged to follow the visit schedule throughout the entire study. If a patient 
chooses to end study participation he/she will be asked to return to the study site as soon as possible for an early terminat ion 
visit. Imaging assessments need to be repeated if it has been >[ADDRESS_406592] imaged. If it has been ≤30 days 
since imaging assessments were completed, imaging assessments may be completed at the discretion of the investigator.  
2. HIV and/or hepatitis testing will be performed on a country -by-country basis, according to local guidelines if required by 
[CONTACT_25035].  Patients must complete all other inclusion/exclusion assessments before undergoing the 
nerve conduction assessments.  
3. Only for patients who provide written informed conse nt for the optional genomics sub -study.  The sample should be collected at 
the day 1 (baseline/randomization) visit, but may be collected at any visit during the study after a patient has been randomi zed. 
4. At the screening and pre -randomization visits, stud y staff will review the “Participating in a Research Study: What You Need to 
Know” brochure and the “Reporting Your Pain” brochure with patients to ensure they understand what a clinical study is and 
how to report their pain accurately. At subsequent visit s, patients will be asked to review the ‘Reporting Your Pain’ brochure 
themselves.  At any time during the conduct of the study, patients may require retraining by [CONTACT_464].  
5. Study drug administration will be the last procedure at each dosing visit, and will be administered after all laboratory, PK, ADA, 
and research samples have been collected and all study related activities have been performed. Patients will be observed in t he 
clinic for approximately 1 hour after SC study drug is administered . 
6. Use of study -provided rescue medication will be recorded daily using diaries. Acetaminophen/paracetamol use will be reported 
from pre -randomization visit to week  16. 
7. The WOMAC pain sub -scale will be evaluated for both knees and both hip joints at the screening vi sit only. Then, the WOMAC 
Full Survey will be completed only for the index joint at the subsequent visits.  
8. Nerve conduction can be performed during screening or pre -randomization. Patients must complete all other inclusion/exclusion 
assessments before unde rgoing the nerve conduction assessments. Randomization cannot occur until there is confirmation from 
the central reader assessment that the results are within the established parameters.  
9. Nerve conduction assessments should be performed at the early termin ation visit if it has been >[ADDRESS_406593] nerve 
conduction assessment.  
10. Blood pressure measurements to assess for orthostatic hypotension may be discontinued following regulatory approval if the 
safety database does not reveal an imbalance for the fasinumab -treated patients.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 46 of 83 
CONFIDENTIAL  11. If the pulse is less than 45 bpm at any visit, an ECG with rhythm strip will be obtained and sent to the central reader to co nfirm 
the heart rate and rhythm.  
12. Imaging (X -ray and/or MRI) will be performed at the investigator’s di scretion on any joint with worsening or exacerbation of 
pain beyond the fluctuations in pain typi[INVESTIGATOR_73411]’s OA. This imaging will be submitted to the adjudication committee 
for review .  
13. If screening radiographs are inconclusive for potential jo int related findings, an MRI must be performed.  Confirmation from the 
central reader that there are no exclusionary findings on the MRI must be received before a patient can be randomized.  
14. In the event that a patient must undergo JR surgery during the st udy, the patient must complete the pre -operative visit (early 
termination assessments, as applicable) and the procedures outlined in the schedule of events for JR follow -up. This will include 
a Knee Society Score questionnaire for knee replacements or Harr is Hip Score questionnaire for hip replacements.  The 
pre-operative visit must be completed before the JR surgery. Pre -operative images will be submitted to the adjudication 
committee for review.  
15. If the AA joint(s) has undergone JR, an X -ray may be substit uted for an MRI.  
16. The purpose of this phone contact [CONTACT_329113]/she has had or is scheduled (or on a waiting list) to have JR s urgery. 
Pre-operative images will be submitted to the central reader for adjudication, if available.  
17. Samples will be analyzed by [CONTACT_329114].  
18. Assessment o f follicle -stimulating hormone ( FSH) and estradiol levels are only to be performed if assessment of postmenopausal 
status is required (ie, for female patie nts ≤59 years of age).  
19. In the event of a positive urine pregnancy test result, the patient must have a serum pregnancy test with a negative result i n order 
to continue study drug. If the serum pregnancy test is positive, the patient must be withdrawn from study drug and should be 
asked to return to the clinic for all remaining study visits per the visit schedule.  
20. Collection of samples for PK, ADA, and research are mandatory at the time points specified above.  In addition, PK, ADA, and 
research samples may be drawn at any scheduled visit or unscheduled visit if a patient experiences a treatment -related safety 
TEAE.  Samples should be collec ted prior to study drug administration on study drug dosing days.  
21. Biomarker samples should be collected after the patients have been fasting overnight or for 8 hours (in the event of an after noon 
visit).  
22. Patient -reported outcome measures should be complete d before any  clinical  assessments.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.  Page 47 of 83 
CONFIDENTIAL  Table  2: Follow -up Period for Patients Undergoing Joint Replacement Surgery on Study  
 Post-Operative  Long -Term  
Follow -up Study Day (Visit Window)1 Follow -up Visit 1  
4 weeks after joint replacement surgery  Follow -up Visit 2  
20 weeks after joint replacement surgery  
Follow -up Day 29 (±5)  Follow -up Day 140 (±7) 
Treatment:   
Concomitant medications and therapy  X X 
Safety:   
Adverse events  --------------------------------------------------------------  
Vital signs  X X 
Orthostatic blood pressure2 X X 
Physical examination with joint examination  X X 
Medical history related to the joint replacement  X X 
Joint pain questionnaire  X X 
Post-operative questionnaire3 X X 
Bilateral X -rays (shoulders, hips, knees)[ADDRESS_406594] be collected, including placement of the prosthesis, healing 
of the surgical wound and the results of the histopathologic examination.  
2. If it is not possible to obtain orthostatic blood pressure following JR then blood pressure and pulse sho uld be recorded.  
3. A Knee Society Score questionnaire for knee replacements or Harris Hip Score questionnaire for hip replacements.  
4. In the event of more than 1 JR, imaging assessments should be repeated if it has been >[ADDRESS_406595] ima ged. 
If it has been ≤60 days since imaging assessments were completed, imaging assessments may be completed at the discretion of 
the investigator. An MRI may be requested by [CONTACT_329115] X -rays.  
5. Imaging will be done at week 4 if no t done pre -operatively.  
6. Imaging may be performed on any joint following a report of clinically significant worsening or exacerbation of pain in that 
joint.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406596] the patient complete 
an early termination visit (as outlined in Table  1). Imaging assessments need to be repeated if it 
has been >[ADDRESS_406597] imaged. If it has been ≤30 days since imaging 
assessments were completed, imaging assessments may be completed at the discretion of the 
investigator.  
8.1.4.  Unschedule d Visits  
All attempts should be made to keep patients on the study schedule.  Unscheduled visits may be 
necessary to repeat testing following abnormal laboratory results, for follow -up of AEs, or for any 
other reason, as warranted.  
8.2. Study Procedures  
8.2.1.  Procedu res Performed Only at the Screening/Baseline Visit  
The following procedures will be performed at the screening visit for the sole purpose of 
determining study eligibility or characterizing the baseline population:  
[IP_ADDRESS].  Main Study Informed Consent  
All patients must sign and date the Institutional Review Board (IRB)/Ethics Committee 
(EC) -approved written informed consent form (ICF) before study procedures are performed, per 
Section  14.2. 
[IP_ADDRESS].  Genomics Sub -study Informed Consent  
Patients who are willing to participate in the Genomics Sub -study, which is optional, will sign the 
consent form prior to the collection of samples. Samples for DNA extraction should be co llected 
on day 1/baseline (pre -dose), but may be collected at any study visit.  
[IP_ADDRESS].  Medical History  
The investigator or designee will take a complete medical history that includes information on 
concurrent medical conditions and the severity for each condition that has not resolved. This 
history will include a patient’s history of surgical procedures.  
[IP_ADDRESS].  Medication History  
The investigator or designee will query patients on the medication(s) they have taken. This 
includes medication taken for their pain due to OA (medication history), including information on 
their ability to tolerate the medication, and will record the info rmation on an electronic case report 
form (eCRF) for this purpose.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 49 of 83 
CONFIDENTIAL  [IP_ADDRESS].  Demographics  
A patient’s demographic characteristics will be recorded, including age, height, weight, gender, 
race, and ethnicity.  
[IP_ADDRESS].  Determination of Osteoarthritis  
Diagnosis of OA of the knee or hip will be based on the American College of Rheumatology 
criteria with radiologic evidence of OA (K-L score ≥2).  
In addition, diagnosis of OA of the hip and knee will use the following criteria:  
Hip 
The American College of R heumatology clinical and radiographic criteria for the diagnosis of OA 
of the hip ( Altman  1991 ) should be used to confirm a diagnosis of OA of the hip, as applicable, at 
screening. The criteria consist of the following combination s: 
 Hip pain, and  
 At least 2 of the following  3 features:  
 Erythrocyte sedimentation rate (ESR) <20 mm/hour  
 Radiographic femoral or acetabular osteophytes  
 Radiographic joint space narrowing (superior, axial, and/or medial)  
Additional information is provided  in the study reference manual.  
Knee  
The American College of Rheumatology clinical and radiographic criteria for the diagnosis of OA 
of the knee ( Altman  1986 ) should be used to confirm a diagnosis of OA of the knee, as applicable,  
at screening.  The criteria consist of the following combinations:  
 Knee pain  
 Osteophytes on radiograph  
 At least 1 of the following 3 features : 
 Age >50 years  
 Stiffness <30 minutes  
 Crepi[INVESTIGATOR_329087].  
[IP_ADDRESS].  Assessment of Childbearing Potential  
Each female patient should be evaluated for childbearing potential.  
Women will be considered to be of childbearing potential unless they are postmenopausal, or have 
had a tubal ligation, a bilateral oophorectomy, bilateral salpi[INVESTIGATOR_1656], or complete hysterectomy.  
For women ≥[ADDRESS_406598] 12 continuous months of 
spontaneous amenorrhea. In women ≤[ADDRESS_406599] 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 50 of 83 
CONFIDENTIAL  12 continuous months of spontaneous amenorrhea, with serum FSH levels >40  IU/L 
(>40  mIU/mL) and serum estradiol levels <5 ng/dL (<184 pmo l/L) (Section  [IP_ADDRESS] ). 
[IP_ADDRESS].  Diary Training  
At the screening and pre -randomization visits, patients will be trained on the use of the diary to 
report their daily acetaminophen/paracetamol use for OA and other non -OA-related reasons. 
Retraining should occur as needed throughout the conduct of the study.  
[IP_ADDRESS].  Patient Education Brochures  
At the screening and pre -randomization visits, study staff will review the  “Participating in a 
Research Study: What You Need to Know” brochure and the “Reporting Your Pain” brochure 
with patients to ensure they understand what a clinical study is and how to report their pain 
accurately. At subsequent visits, patients will be ask ed to review the ‘Reporting Your Pain’ 
brochure themselves.  At any time during the conduct of the study, patients may require retraining 
by [CONTACT_464].  
8.2.2.  Patient -Completed Assessments and Efficacy Procedures  
[IP_ADDRESS].  Western Ontario and McMaster Universities Osteo arthritis Index  
The WOMAC index is used to assess patients with OA of the hip or knee using 24  parameters and 
reported using a numerical rating scale. This index can be used to monitor the course of a disease 
or to determine effectiveness of study drugs. T he WOMAC pain sub -scale will be evaluated for 
both knees and both hip joints at the screening visit. Then, patients will complete the WOMAC 
Full Survey on the index joint at the subsequent visits, as indicated in  Table  1. If possible, the 
assessment should be administered and entered by [CONTACT_73472].  
The WOMAC index is a p atient -reported outcome measure  and should be completed along with 
other patient -reported outcome measures , but before any clinical  assessments.  
A copy of WOMAC assessments will be provided in the study reference manual.  
8.2.3.  Neurological Assessments  
[IP_ADDRESS].  Nerve Conduction  
Nerve conduction velocities and evoked amplitudes  of the peroneal motor, sural sensory and ulnar 
sensory nerves will be assessed at the time points indicated in  Table  1. Motor nerve conduction is 
evaluated by [CONTACT_329116] a muscle supplied by [CONTACT_329117]  (Mallik  2005 ). Sensory 
nerve conduction is evaluated by [CONTACT_329118] a point further along that nerve  (Mallik  2005 ). Data  will be interpreted by a 
central reader. Complete guidance on how to perform the nerve conduction assessme nts and how 
to report the findings is provided in the study reference manual.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 51 of 83 
CONFIDENTIAL  [IP_ADDRESS].  Neurological Examination (Full)  
A full neurological examination will be performed at the time points indicated in  Table  1.  
Neurological findings at baseline that are not exclusionary should be recorded in the medical 
history. Findings at subsequent visits will be assessed by [CONTACT_329119].  
The neurological examination will cover the following domains: motor, sensory, cranial nerves, 
reflexes, and coordination/balance and assessment for presence/absence of signs of carpal tunnel 
syndrome and may be conducted by  [CONTACT_73480]. Whenever possible, 
the same clinician who conducts the baseline neurological examination should continue to conduct 
the examinations on a given patient. The investigator may refer patients with persistent or 
worsening neurologic symptoms for a neurologic consultation, if clinically indicated. Additional 
neurologic assessments may include other tests as deemed clinically necessary in the judgement 
of the neurologist.  
Complete guidance on how to conduct the full  neurologic examination is provided in the study 
reference manual.  
[IP_ADDRESS].  Survey of Autonomic Symptoms  
The survey of autonomic symptoms will be completed by [CONTACT_329120]  1. The completed survey will be reviewed for signs and symptoms of autonomic 
dysfunction by [CONTACT_093]/medical designee at each visit prior to study drug injection at the 
time points indicated in Table  1. If possible, the assessment should be completed by [CONTACT_73478].  A patient report of having experienced symptoms of autonom ic 
dysfunction will serve as a tool to prompt further evaluations as deemed necessary by [CONTACT_329121].  
Survey of Autonomic Symptoms is a p atient -reported outcome measure and  should be completed 
along with other patient -reported out come measures , but before any clinical  assessments.  
A copy of the survey is provided in the study reference manual.  
[IP_ADDRESS].  Orthostatic Blood Pressure Assessment and Heart Rate  
An assessment of orthostatic blood pressure will be conducted at the time points indica ted in  
Table  1. The assessments should be conducted as per the instructions in the study manual. A patient 
will be determined to have orthostatic hypote nsion if any of the following criteria are met:  
If the supi[INVESTIGATOR_329088] <160 mm Hg, a decrease in either the 1 or 3 minute standing 
systolic blood pressure of ≥20 mm Hg or a decrease in the standing diastolic blood pressure of ≥10 
mm Hg fr om the supi[INVESTIGATOR_73416], respectively  
OR 
If the supi[INVESTIGATOR_329088] ≥160 mm Hg, a decrease in either the 1 or 3 minute standing 
systolic blood pressure of ≥30 mm Hg or a decrease in the standing diastolic blood pressure of ≥15 
mm Hg from the supi[INVESTIGATOR_73416], respectively  
OR 
An increase in either the 1 or 3 minute standing heart rate of ≥30 bpm from the supi[INVESTIGATOR_329089]-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 52 of 83 
CONFIDENTIAL  OR 
The patient is unable to stand for either one of the standing blood pressure measurements due to 
dizziness or lightheadedness  
If the initial assessment for orthostatic hypotension is consistent with the above definition, the 
supi[INVESTIGATOR_73418]/or pulse should be repeated as outlined above, up to 
2 more times.  
Refer to Section  [IP_ADDRESS]  for details on referral to specialists and reporting.  
8.2.4.  Safety Procedures  
[IP_ADDRESS].  Vital Signs  
Vital signs, including b ody temperature and respi[INVESTIGATOR_697], will be collected pre -dose at time 
points according to Table  1. Blood pressure and heart rate will be collected as  part of the orthostatic 
hypotension assessments. If at any visit after the randomization visit the pulse is less than 45  bpm, 
an ECG with rhythm strip will be obtained to confirm the heart rate and rhythm.  
[IP_ADDRESS].  Electrocardiogram  
A standard 12 -lead ECG will be performed at the time points indicated in Table  1, with the patient 
in the supi[INVESTIGATOR_73414] 5 minutes and prior to blood samples being  drawn. Heart 
rate will be recorded from the ventricular rate, and the PR, QRS, and the QT and QTc intervals 
will be recorded. The ECG data will be read by a central reading center. Detailed procedures will 
be provided in a separate manual provided by [CONTACT_73475].  
[IP_ADDRESS].  Physical Examination and Body Weight  
A thorough and complete physical examination will be performed at time points according to 
Table  1. Body weight will also be measured.  Care should be taken to examine and assess any 
abnormalities that may be present, as indicated by [CONTACT_102]’s medical history.  
[IP_ADDRESS].  Joint Pain Questionnaire  
A joint pain questionnaire will be completed by [CONTACT_329122]  1. 
For each knee, hip, and shoulder joint, the patient will be prompted to indicate if he or she has 
experienced pain. A patient report of having experienced pain will serve as a tool to prompt further 
evaluations as deemed necessary by [CONTACT_093].  
Joint Pain Questionnaire is a p atient-reported outcome measure and should be completed along 
with othe r patient -reported outcome measures , but before any clinical  assessments.  
A copy of the assessment is provided in the study reference manual.  
[IP_ADDRESS].  Imaging  
Radiographs of the large joints (knees, hips, and shoulders) will be taken using a standard approach 
at the time points indicated in Table  1.  An MRI of the index and contralateral joints must be 
performed at screening. Magnetic resonance imaging will also b e performed on any hip or knee 
joint with a K˗L score of ≥3.  Radiographs and an MRI  must be performed on any joint following 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 53 of 83 
CONFIDENTIAL  a report of clinically significant worsening or exacerbation of pain in that joint. An X˗ray and an 
MRI should also be performed p re-operatively if a patient is to have a JR during the study. Event 
based and pre -operative images will be submitted for adjudication. Detailed procedures will be 
provided in a separate manual provided by [CONTACT_63379].  Radiograph or MRI will  be 
sent to a central reader, where the images will be digitized.  
Radiographs  
Weight -bearing (standing) posterior -anterior radiographs of both knees in the semi -flexed 
position, and anterior -posterior radiographs of both hips and both shoulders, will be c onducted at 
these visits.  Additional instructions for positioning of joints are provided in the study reference 
manual.  
Radiographs of the knees, hips, and shoulders will be sent to a central reader and evaluated to 
confirm no evidence of AA such as rapid ly progressive osteoarthritis type 1 or 2, subchondral 
insufficiency fracture, or osteonecrosis.  
MRI  
During screening, MRIs of the index and contralateral joints as well as joints with a K -L score ≥[ADDRESS_406600] an MRI performed of the 
affected joint(s). If the affect joint has un dergone JR, an X -ray may be substituted for an MRI.  
Refer to the supplemental imaging manuals for data collection and management procedures.  
[IP_ADDRESS].  End of Study Phone Contact [CONTACT_329123] [ADDRESS_406601] in -clinic visit of the 
follow -up period or whether they are scheduled (or on a waiting list) for JR surgery.  Patients who 
had JR surgery will als o be asked to submit pre -operative imaging (X -ray and MRI, if available) 
for adjudication. Patients who had an AA will have an MRI performed of the affected joint(s). If 
the affected joint has undergone JR, an X -ray may be substituted for an MRI.  
[IP_ADDRESS].  Procedures to be Performed Only in the Event of a Joint Replacement Surgery  
In the event that a patient must undergo JR surgery during the treatment or follow -up periods, the 
patient will be discontinued from study drug and asked to return for a pre -operative visit. The pre -
operative visit should be completed before JR surgery if possible, and pre -operative images will 
be submitted to the adjudication committee for review.  Following the JR surgery, the patient will 
complete follow -up safety evaluations at 4 weeks and 20 weeks after surgery (see Table  2). 
In the event that the pre -operative visit is not performed, standard -of-care pre -operative images of 
the joint with JR must be obtained and submitted to the central imaging vend or's adjudication 
committee for review.  Imaging of all other joints per the pre -operative visit procedures will be 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406602] JR follow -up study visit (4 weeks after surgery) if not done before 
surgery.  
All available medical histor y/information for patients who undergo JR surgery must be collected, 
including the results of histopathologic examination.  
Full details of these assessments are provided in the study reference manual.  
Knee Society Score  
The Knee Society Score is an investi gator -completed questionnaire that is used to objectively 
measure a patient’s ability to function before and after total knee arthroplasty ( Insall  1989 ). If 
possible, the assessment should be completed by [CONTACT_329124] t the study.  
Harris Hip Score  
The Harris Hip Score is an investigator -completed questionnaire that is used to objectively 
measure a patient’s ability to function before and after total hip arthroplasty ( Harris  1969 ). If 
possible, the assessment should be completed by [CONTACT_73472].  
[IP_ADDRESS].  Laboratory Testing  
The central laboratory will analyze all screening and on -study laboratory samples for blood 
chemistry, hematology, HbA1c, urine analysis, urine drug tests, and s erum pregnancy tests.  Urine 
pregnancy and ESR testing will be done at the site using kits provided by [CONTACT_2237].  
Regeneron or its designee will be responsible for fasinumab PK, anti -fasinumab antibody, 
biomarker development, and pharmacogenet ic sample assessments; the central laboratory will ship 
the samples to Regeneron or a specialty laboratory depending on the assessment.  
All samples will be collected before study drug administration.  Missed tests should be reported in 
the source documents  and in the eCRF, as appropriate.  Central laboratory kits will be provided 
for sample collection and shipment.  Detailed instructions for blood sample collection are in the 
laboratory manual provided to study sites.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 55 of 83 
CONFIDENTIAL  Samples for laboratory testing will be collected at time points according to Table  1. Tests will 
include:  
Blood Chemistry  
Sodium  Total protein, serum  Total bilirubin  
Potassium  Creatinine  Phosphorus  
Chloride  Blood urea nitrogen  Uric acid  
Carbon dioxide  Aspartate aminotransferase (AST)  Creatine phosphokinase  
Calcium  Alanine aminotransferase (ALT)   
Glucose  Alkaline phosphatase   
Albumin  Lactate dehydrogenase   
Hematology  
Hemoglobin  Differential:  
Hematocrit  Neutrophils  
Red blood cells (RBCs)  Lymphocytes  
White blood cells (WBCs)  Monocytes  
Red cell indices  Basophils  
Platelet count  Eosinophils  
Urinalysis  
Color  Glucose  RBC  
Clarity  Blood  Hyaline and other casts  
pH Bilirubin  Bacteria  
Specific gravity  Leukocyte esterase  Epi[INVESTIGATOR_73420] (WOCBP) (as defined in Section  [IP_ADDRESS] ) at time points according to Table  1. At dosing 
study visits, urine pregnancy testing will be done before the study drug is administered. In the 
event of a posi tive urine pregnancy test result, the patient should have a serum pregnancy test with 
a negative result in order to continue study drug. If the serum pregnancy test is positive, the patient 
should be withdrawn from study drug and should be asked to return to the clinic for all remaining 
study visits per the visit schedule (see Table  1). 
To assess postmenopausal status for women ≤[ADDRESS_406603] for FSH levels 
and estradiol levels will be collected for analysis at the central laboratory according to 
Section  [IP_ADDRESS] . 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 56 of 83 
CONFIDENTIAL  Samples will be collected for HbA1c and ESR testing at time points according to Table  1. 
Urine drug testing will be performed at screening and includes amphetamines/methamphetamines, 
barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine, and opi[INVESTIGATOR_858].  
Blood samples for study drug PK a nd ADA assessment  (Section  8.2.5 ) will also be collected.  
Abnormal Laboratory Values and Laboratory Adverse Events  
All laboratory values must be rev iewed by [CONTACT_31594].  
Significantly abnormal test results that occur after start of treatment must be repeated to confirm 
the nature and degree of the abnormality. When necessary, appropriate ancillary investigations 
should be i nitiated. If the abnormality fails to resolve or cannot be explained by [CONTACT_25037], the medical monitor must be 
consulted.  
The clinical significance of an abnormal test value, within the con text of the disease under study, 
must be determined by [CONTACT_093].  
Criteria for reporting laboratory values as an AE are provided in Section  9.4.5 . Evaluation of 
severity of laboratory abnormalities will be assessed according to the scale outlined in 
Section  9.5.1 . 
[IP_ADDRESS].  Injection Site Evaluations  
An injection site evaluation should be conducted following the injection at each dosing visit, 
according to Table  1.  
8.2.5.  Pharmacokinetic and Anti -Drug Antibody Procedures  
[IP_ADDRESS].  Drug Concentration Measurements and Samples  
Samples for drug concentration will be collected at time points listed in Table  1. Detailed 
instructions for blood sample collection are included in the laboratory manual provided to study 
sites.  
Any unused samples may be used for exploratory biomarker research.  
[IP_ADDRESS].  Anti -Drug Antibody Measurements and Samples  
Samples for ADA assessment will be collected at time points listed in Table  1. Detailed 
instructions for blood sample collection are included in the laboratory manual provided to study 
sites.  
Any unused samples may be used for exploratory biomarker research.  
8.2.6.  Research Samples  
[IP_ADDRESS].  Biomarkers  
Serum and plasma samples will be collected at t ime points according to Table  1. These samples 
may be used to measure biomarkers related to inflammation, collagen and bone turnover, OA pain 
and NGF a nd may include CTX -I, osteocalcin, high -sensitivity C -reactive protein and matrix 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 57 of 83 
CONFIDENTIAL  metalloprotein generated collagen fragments (CIM, C3M).  Samples may be used to study other 
markers of collagen and bone turnover, OA and pain.  If necessary, samples may als o be used to 
identify markers associated with AEs.  
[IP_ADDRESS].  Future Biomedical Research  
Unused research samples, as well as unused PK and ADA samples, will be stored for up to 15  years 
after the final date of the database lock. The unused samples may be utilized for  future biomedical 
research of OA and other diseases. No additional samples will be collected for future biomedical 
research. After 15 years, any remaining samples will be destroyed.  
[IP_ADDRESS].  Genomics Sub -study - Optional  
Patients who agree to participate in the ge nomics sub -study will be required to sign a separate 
genomics sub -study ICF before collection of the samples. Patients are not required to participate 
in the genomics sub -study in order to enroll in the primary study. Samples for DNA extraction 
should be c ollected on day 1/baseline (pre -dose), but may be collected at any study visit.  
DNA samples for the genomics sub -study will be double -coded as defined by [CONTACT_329125] (ICH) guideline E15. Sub -study samples will be stored for  up to [ADDRESS_406604] of methods may be expanded to include novel 
methodology that may be developed during the course of this study or sample storage period.  
The results of these future biomedical research analyses will not be presente d in the clinical study 
report.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406605] promptly report to the IRB or EC all unanticipated problems involving risks 
to patients, according to local regulations. This ma y include death from any cause and all serious 
adverse events (SAEs) related to the use of the study drug.  It is recommended that all SAEs be 
reported to the IRB or EC according to local regulations.  
9.2. Obligations of Sponsor  
During the course of the study, the sponsor will report in an expedited manner all SAEs that are 
both unexpected and at least reasonably related to the study drug (S[LOCATION_003]R), to the health 
authorities, EC/IRBs as appropriate, and to the investigators (in a blinded manner).  
Any AE not liste d as an expected event in the Reference Safety Information section of the 
Investigator’s Brochure will be considered unexpected. Any worsening of or new onset of 
symptoms related to OA that occur during the screening period prior to study drug administrati on 
will be considered expected.  
In addition, the sponsor will report all other SAEs to the health authorities, according to local 
regulations.  
At the completion of the study, the sponsor will report all safety observations made during the 
conduct of the tr ial in the clinical study report to health authorities and ECs/IRBs as appropriate.  
9.3. Definitions  
9.3.1.  Adverse Event  
An AE is any untoward medical occurrence in a patient administered a study drug which may or 
may not have a causal relationship with the study dr ug. Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, or disease which is temporally 
associated with the use of a study drug, whether or not considered related to the study drug.  
An AE also includes a ny worsening (ie, any clinically significant change in frequency and/or 
intensity) of a pre -existing condition that is temporally associated with the use of the study drug.  
9.3.2.  Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
 Results in death  – includes all deaths, even those that appear to be completely unrelated 
to study drug (eg, a car accident in which a patient is a passenger).  
 Is life-threatening  – in the view of the investigator, the patient is at immediate risk of 
death  at the time of the event.  This does not include an AE that had it occurred in a 
more severe form, might have caused death.  
 Requires in -patient hospi[INVESTIGATOR_869] .  
In-patient hospi[INVESTIGATOR_24927] a hospi[INVESTIGATOR_73422] 24 hours.  Prolongation of existing hospi[INVESTIGATOR_31561] a 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 59 of 83 
CONFIDENTIAL  hospi[INVESTIGATOR_24929], or is prolonged 
due to the development of a new AE as determined by [CONTACT_28807].  
 Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).  
 Is a congenital anomaly/birth defect  
 Is an important medical eve nt - Important medical events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_059], but may jeopardize the patient or 
may require intervention to prevent one of the other serious outcomes listed above.  
Examples of these include in tensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse.  
Criteria for reporting SAEs must be followed for these even ts. See Section  9.[ADDRESS_406606]  
An AESI (serious or non -serious) is one of scientific and medical concern specific to the sponsor’s 
product or program, for which ongoing monitoring and rapid communication by [CONTACT_25044].  Such an event might warrant further investigation in order to 
chara cterize and understand it.  Depending on the nature of the event, rapid communication by [CONTACT_329126] (eg, regulators) might also be warranted (Section  9.4.3 ). 
9.4. Recording and Reporting Adverse Events  
9.4.1.  Adverse Events  
The investigator (or designee) will record all AEs that occur from the time the informed consent 
is signed until the end of the follow -up period (week 36)/early termina tion visit. Refer to the study 
reference manual for the procedures to be followed.  
Information on follow -up for AEs is provided in Section  9.4.[ADDRESS_406607] be reported to the 
sponsor (or designee) within [ADDRESS_406608] reports may 
also be requested.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 60 of 83 
CONFIDENTIAL  In the event the investigator is informed of an SAE after the patient completes the follow -up period 
(week 36)/e arly termination visit, the following will apply:  
 SAE with an onset within 30 days of the end of the follow -up (week 36)/early 
termination visit  - the SAE will be reported to the sponsor.  The investigator should 
make every effort to obtain follow -up infor mation on the outcome until the event is 
considered chronic and/or stable.  
 SAE with an onset day greater than 30 days from the end of follow -up period 
(week  36)/early termination visit - only SAEs deemed by [CONTACT_329127]-related will be repor ted to the sponsor. The investigator should make every effort 
to obtain follow -up information on the outcome of a drug -related SAE until the event 
is considered chronic and/or stable.  
 SAE reported by [CONTACT_329128] d by [CONTACT_329129] -related will be reported to the sponsor. The investigator should 
make every effort to obtain follow -up information on the outcome of a drug -related 
SAE until the event is considered chronic and/or stable.  
9.4.3.  Other Events that Require Accelerated Reporting to Sponsor  
The following events also require reporting to the sponsor (or designee) within 24 hours of learning 
of the event:  
Symptomatic Overdose of Study Drug:  Accidental or intentional overdose of at least 2  times 
the inten ded dose of study drug within the intended therapeutic window, if 
associated with an AE  
Pregnancy:  Although pregnancy is not considered an AE, it is the responsibility of the 
investigator to report to the sponsor (or designee), within [ADDRESS_406609] dose of study drug. Any complication of pregnancy affecting a 
female study patient and/or fetus and/or newborn that meets the SAE criteria  must 
be reported as an SAE. Outcome for all pregnancies should be reported to the 
sponsor.  
Adverse Events of Special Interest:   All AESI, serious and non -serious, must be reported 
within [ADDRESS_406610] for this study include the following:  
 Adjudicated arthropathy (as confirmed by [CONTACT_73485])  
 Joint replacement surgery (refer to Section  [IP_ADDRESS]  for when to report as an 
AESI)  
 Sympathetic nervous system dysfunction (as diagnosed after consultation 
with an appropriate specialist, such as a neurologist and/or cardiologist)  
 Peripheral sensory AEs that require a neurology or other specialty 
consultation  
Refer to the study manual for the procedures to be followed.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 61 of 83 
CONFIDENTIAL  9.4.4.  Reporting Adverse Events Leading to Withdrawal from the Study  
All AEs that lead to a patient’s withdrawal from the stu dy must be reported to the sponsor’s 
Medical/Study Director within [ADDRESS_406611] finding should be reported as an 
AE include:  
 the test result is associated with accompanying symptoms, and/or  
 the test result requires additional diagnostic testing or medical/surgical intervention, 
and/or  
 the test result leads to a chang e in dosing (outside of protocol -stipulated dose 
adjustments), discontinuation from the study, significant additional concomitant drug 
treatment, or other therapy  
Contact [CONTACT_22951]/Study Director in the event the investigator feels that an abnormal test finding 
should be reported as an AE, although it does not meet any of the above criteria.  
Repeating an abnormal test, in the absence of any of the above conditions, does not constitute an 
AE. Any abnormal test result that is determined to be an error does not require reporting as an AE.  
Evaluation of severity of laboratory abnormalities will be assessed according to the scale outlined 
in Section  9.5.1 .  
9.4.6.  Follow -up 
Adverse  event information will be collected until the  patient’s last study visit.  
Serious adverse event information will be collected until the event is considered chronic and/or 
stable.  
9.5. Evaluation of Severity and Causality  
9.5.1.  Evaluation of Severity  
The severity of AEs will be graded according to the following scale:  
 Mild:  Does not interfere in a significant manner with the patient normal functioning 
level.  It may be an annoyance. Prescription drugs are not ordinarily needed for relief 
of symptoms, but may be given because of personality of the patient.  
 Moderate:   Produces some impairment of functioning but is not hazardous to health. 
It is uncomfortable or an embarrassment. Treatment for symptom may be needed.  
 Severe:   Produces significant impairment of functioning or incapacitation and is a 
definite hazard to the subject’s health. Treatment for symptom may be given and/or 
patient hospi[INVESTIGATOR_057].  
If a laboratory value is considered an AE, its severity should be based on the degree of 
physiological impairment the value indicates.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 62 of 83 
CONFIDENTIAL  Injection Site Reactions  
The severity of injection site reactions will be graded according to the following scale (semi -colon 
indicates “or” within description of grade):  
 Mild :  Pain that does not  interfere with activity; mild discomfort to touch; <5 cm of 
erythema or induration that does not interfere with activity.  
 Moderate :  Pain that requires repeated use of non -narcotic pain reliever >24 hours or 
interferes with activity; discomfort with movem ent; 5.1 cm to 10 cm erythema or 
induration or induration that interferes with activity.  
 Severe :  Pain that requires any use of narcotic pain reliever or that prevents daily 
activity; significant discomfort at rest; >10 cm erythema or induration; prevents daily 
activity; requires emergency room visit or hospi[INVESTIGATOR_059]; necrosis or exfoliative 
dermatitis.  
9.5.2.  Evaluation of Causality  
Relationship of Adverse Events to Study Drug:  
The relationship of AEs to study drug will be assessed by [CONTACT_941] "blinded" investigato r, and will be a 
clinical decision based on all available information. The following question will be addressed:  
Is there a reasonable possibility that the AE may have been caused by [CONTACT_5257]?  
The possible answers are:  
Not Related:  There is no reason able possibility that the event may have been caused by [CONTACT_50464].  
Related:  There is a reasonable possibility that the event may have been caused by [CONTACT_50464].  
The investigator should justify the causality assessment of each SAE.  
A list of factor s to consider when assessing the relationship of AEs to study drug is provided below.  
Please note that this list is not exhaustive.  
Is there a reasonable possibility that the event may have been caused by [CONTACT_5257]?  
No: 
 due to external causes such as  environmental factors or other treatment(s) being 
administered  
 due to the patient’s disease state or clinical condition  
 do not follow a reasonable temporal sequence following the time of administration of 
the dose of study drug  
 do not reappear or worsen w hen dosing with study drug is resumed  
Yes: 
 could not be explained by [CONTACT_28854](s) being 
administered  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 63 of 83 
CONFIDENTIAL   could not be explained by [CONTACT_102]’s disease state or clinical condition  
 follow a reasonable temporal sequence following the time of administration of the dose 
of study drug  
 resolve or improve after discontinuation of study drug  
 reappear or worsen when dosing with study drug  
 are known or suspected to be a response to the stu dy drug based upon preclinical data 
or prior clinical data  
Relationship of Adverse Events to Study Conduct  
The relationship of AEs to study conduct will be assessed by [CONTACT_941] "blinded" investigator, and will 
be a clinical decision based on all available infor mation.  The following question will be addressed:  
Is there a reasonable possibility that the AE may have been caused by [CONTACT_50465]?  
The possible answers are:  
Not Related:  There is no reasonable possibility that the event may have been caused by [CONTACT_50466].  
Related:  There is a reasonable possibility that the event may have been caused by [CONTACT_50466].  
The investigator should justify the causality assessment of each SAE.  
A list of factors to consider when assessing the relationship of AEs to study co nduct is provided 
below. Please note that the list if not exhaustive.  
Is there a reasonable possibility that the event may have been caused by [CONTACT_50467]?  
Is there a reasonable possibility that the event may have been caused by [CONTACT_50467]?  
No: 
 due to external causes such as environmental factors or other treatment(s) being 
administered  
 due to the patient’s disease state or clinical condition  
 do not follow a reasonable temporal sequence following the course of the study  
 do not reappear or worse n when dosing with study participation is resumed  
Yes: 
 could not be explained by [CONTACT_28854](s) being 
administered  
 could not be explained by [CONTACT_102]’s disease state or clinical condition  
 follow a reasonable temporal sequenc e following the course of the study  
 resolve or improve after discontinuation from study participation.  
 reappear or worsen when study participation is resumed  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 64 of 83 
CONFIDENTIAL  9.6. Safety Monitoring  
The investigator will monitor the safety of study patient at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP). Any questions or 
concerns should be discussed with the sponsor in a timely fashion. The sponsor will monitor the 
safety data from across all study sites. The Me dical/Study Director will have primary responsibility 
for the emerging safety profile of the compound, but will be supported by [CONTACT_25047] 
(eg, Pharmacovigilance and Risk Management; Biostatistics and Data Management). Safety 
monitoring will be perf ormed on an ongoing basis (eg, individual review of SAEs) and on a 
periodic cumulative aggregate basis.  
9.6.1.  Monitoring Adverse Events of Special Interest  
[IP_ADDRESS].  Adjudicated Arthropathy  
Adjudicated arthropathy is an umbrella term that encompasses the following conditi ons: 
 Rapi[INVESTIGATOR_73405] 1 and 2  
 Subchondral insufficiency fractures  
 Primary osteonecrosis  
In addition, adjudicated arthropathies will be evaluated to determine if they meet destructive 
arthropathy criteria.  
Potential events of AA will be monitored  via clinical signs and symptoms of worsening joint pain 
during the course of the study (eg, by [CONTACT_73487], the joint pain questionnaire 
and imaging) as well as scheduled imaging and pre -operative imaging, if a patient requires a JR 
durin g the study.  
Clinically significant worsening of joint pain during the course of this study is characterized as a 
worsening of pain in any joint that occurs in spi[INVESTIGATOR_73423], is in the opi[INVESTIGATOR_329090], and is at 
least 2 weeks duration (or less than 2 weeks if deemed clinically significant at the discretion of the 
investigator).  
If a patient reports an increase in pain as described above, study drug adminis tration will be 
withheld while imaging of the affected joint , as well as any additional imaging deemed appropriate 
to understand the cause of the worsening pain, is performed ( Section  [IP_ADDRESS] ). A decision to 
perform imaging after patient reported of worsening of joint pain will be documented in the 
respective CRF page. Images, along with any other radiographic evaluation, will be submitted to 
the arthropathy adjudication committee for review ( Section  5.3.2 ). The investigator may consider 
aspi[INVESTIGATOR_329091] r analysis such as cell count and crystal analysis.  
If routine imaging suggests the presence of one of the types of AA, study drug administration will 
be withheld. Any additional imaging deemed appropriate will be obtained. The images, along with 
results of any other radiographic evaluation, will be submitted to the Adjudication Committee for 
review ( Section  5.3.2 ).  
If the adjudication does not confi rm the presence of AA, according to the adjudication criteria, 
study drug may be restarted.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406612] AA; 
the patients will be referred for orthopedic consultation . If presenc e of AA is confirmed by [CONTACT_21662], the case must be reported as an AESI (Section  9.3.3  and Section  9.4.3 ).  
Any patient whose study drug is discontinued due to an AA should be encouraged to return to the 
clinic for all remaining study visits. If JR surgery is warranted, prior to the scheduled JR, the 
patient should complete the pre -operative study visit and, after the JR, should complete the week 
[ADDRESS_406613] -operative study visits ( Table  2).  Pre -operative images, along with any other 
radiographic evaluation will be submitted to the arthropathy adjudication committee for review 
(Section  5.3.2 ). 
Details of data collection for adjudication of events will be provided in the adjudication charter.  
[IP_ADDRESS].  Sympathetic Nervous System Dysfunction  
Sympathetic nervous system dysfunction will be monitored throughout the study through ph ysical 
examination, AE reporting, assessment of orthostatic hypotension, and the Survey of Autonomic 
Symptoms ( Section  [IP_ADDRESS] ). New onset or worsen ing of signs and symptoms of autonomic 
dysfunction will be evaluated by [CONTACT_093].  Sympathetic nervous system dysfunction will 
only be diagnosed after consultation with an appropriate specialist, such as a neurologist and/or 
cardiologist.  
In cases in which new or worsening symptoms consistent with SNS dysfunction are moderate to 
severe or are clinically significant and do not resolve or return to baseline in 2  weeks (or less at 
the discretion of the investigator), study drug will be withheld and the  patient will be referred to a 
specialist. If the evaluation by [CONTACT_329130], study 
drug may be restarted. If the specialist’s evaluation does reveal SNS dysfunction then study drug 
will be permanently discont inued and the case reported as an AESI ( Section  9.4.3 ). 
Orthostatic hypotension may be a manifestation of SNS dysfunction. If a patient is determined  to 
have orthostatic hypotension, study drug should be withheld and the AE should be entered in the 
CRF. The following procedures should be followed:  
 If the patient is symptomatic and a clinical explanation for orthostatic hypotension is 
identified (such a s a new medication or dehydration due to exercise or illness or 
excessive heat exposure), study drug will be withheld, and the patient should return to 
the study site for an unscheduled visit in 1 to 10 days for an unscheduled assessment 
of orthostatic hyp otension.  
 If the orthostatic hypotension has resolved, study drug may be restarted.  
 If the orthostatic hypotension has not resolved, then study drug will be withheld, 
and the patient will be referred to a specialist (neurologist or a cardiologist) for 
evaluation of sympathetic nervous system dysfunction.  
 If the specialist’s evaluation does not reveal new onset SNS dysfunction, 
including symptoms of bradycardia (lightheadedness), orthostatic 
hypotension (lightheadedness on standing), syncope, absence of sweating 
in conditions where sweating would be expected, or if the specialist’s 
evaluation identifies an alternative cause, such as initiation of a new 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 66 of 83 
CONFIDENTIAL  medication known to cause orthostasis, then study drug may be given at the 
next visit.  
 If the specialist ’s evaluation  does reveal SNS dysfunction, then study drug 
will be permanently discontinued and the case reported as an AESI 
(Section  9.4.3 ). 
 If the patient has asymptomatic orthostatic hypotension, study drug will be withheld, 
and the patient should return to the study site for an unscheduled visit in 1 to 10 days 
for an unscheduled assessment of orthostatic hypotension.  
 If the unscheduled assessment does not reveal orthostatic hypotension then study 
drug may be continued.  
 If the unscheduled assessment demonstrates orthostatic hypotension then study 
drug will continue to be withheld until the patient has been evaluated by a specialist 
(neurologist or a  cardiologist) for evidence of SNS dysfunction.  
 If the specialist’s evaluation does not reveal new SNS dysfunction including 
symptoms of bradycardia (lightheadedness), orthostatic hypotension 
(lightheadedness on standing), syncope, absence of sweating in c onditions 
where sweating would be expected, or if the specialist’s evaluation 
identifies an alternative cause such as initiation of a new medication known 
to cause orthostasis, then study drug may be restarted.  
 If the specialist’s evaluation does reveal SN S dysfunction then study  drug 
will be permanently discontinued and the case reported as an AESI 
(Section  9.4.3 ). 
[IP_ADDRESS].  Peripheral Sensory Adverse Events  
Altered peripheral sensation (eg, paraesthesia and hypoaesthesia) is an important identified risk 
with fasinumab (see Investigator’s Brochure) and other anti -NGF compounds. Any peripheral 
sensory AE that, per the investigator’s judgment , requires a neurolog y or other specialty 
consultation must be reported as an AESI. If any peripheral sensory event persists for [ADDRESS_406614] -baseline visit shows a difference from ba seline of >12% (based on 
central reader assessment), the patient  will be referred for a neurology evaluation.  If the 
neurologist’ s evaluation confirms the diagnosis of peripheral neuropathy , the study drug will be 
permanently discontinued .  Refer to the study manual for further details related to reporting of 
results of nerve conduction tests . 
[IP_ADDRESS].  Joint Replacement Surgery  
Any elective JR surgery planned before completion of the ICF would be part of the exclusion 
criteria and would not be conside red an AE.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 67 of 83 
CONFIDENTIAL  After signing of the ICF, report JR surgery as an AESI if the JR surgery is an elective event that is 
not associated with a new/worsening AE.  
Do not report JR surgery as an AE/AESI if the JR surgery is for the treatment of a new or worsening 
AE. In this case, the new or worsening AE should be the reported AE/AESI term.  
An end of study phone contact [CONTACT_38877] [ADDRESS_406615] undergone or are scheduled for JR 
surgery as described in Section  [IP_ADDRESS] . 
9.7. Investigator Alert Notification  
Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as 
in any other clinical trial using the same investigational drug, of any SAE that meets the relevant 
requirements for expedited reporting (an AE that is serious, unexpected based on the Investigator’s 
Brochure or this prot ocol, and has a reasonable suspected causal relationship to the 
medicinal/study drug).  
10. STATISTICAL PLAN  
This section provides the basis for the statistical analysis plan (SAP) for the study.  The SAP may 
be revised during the study to accommodate amendmen ts to the clinical study protocol and to make 
changes to adapt to unexpected issues in study execution and data that may affect the planned 
analyses.  The final SAP will be issued before the database is locked.  
Analysis variables are listed in Section  4. 
10.1. Statistical Hypothesis  
No formal hypothesis testing will be performed on nerve conduction measures. The treatment 
difference between fasinumab and pla cebo in the change from baseline to week 16 in nerve 
conduction measures will be estimated and presented descriptively along with 95% confidence 
intervals.  
10.2. Justification of Sample Size  
Approximately 180 patients will be randomized in a 1:1 ratio to fasinum ab 1 mg Q4W or placebo.  
With this sample size, the precision of the estimated treatment difference between fasinumab and 
placebo at week 16 in nerve conduction velocity is no more than 1.21 m/s with a 95% confidence 
level, assuming a standard deviation (S D) of 3.6 m/s. This sample size provides similar precision 
for the estimated treatment difference in nerve conduction amplitude assuming an SD of 3.6 μV. 
The assumed SDs are estimated based on the nerve conduction results from Arezzo 2008 . 
Assuming a 2 -sided alpha level of 0.05 and a 15% dropout rate up to week 16, an enrollment of 
[ADDRESS_406616] 80% power to detect an effect size of 0.46 in the 
WOMAC pain and physical function subscale scores (ie, absolute treat ment difference of 1.1 
between fasinumab and placebo with an SD of 2.4). The assumed treatment difference and SD are 
based on results from study R475 -PN-1227.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 68 of 83 
CONFIDENTIAL  10.3. Analysis Sets  
10.3.1.  Efficacy Analysis Set  
The full analysis set (FAS) includes all randomized patient s and is based on the treatment allocated 
(as randomized).  Efficacy endpoints will be analyzed using the FAS.  
10.3.2.  Safety Analysis Set  
The safety analysis set (SAF) includes all randomized patients who received any study drug; it is 
based on the t reatment received (as treated).  Treatment compliance/administration and all clinical 
safety variables will be analyzed using the SAF.  
10.3.3.  Pharmacokinetic Analysis Set  
The PK analysis set includes all treated patients who received any study drug and who had at  least 
[ADDRESS_406617] 1 qualified (non -missing) post -
dose ADA result following the first do se of study drug.  
10.4. Statistical Methods  
For continuous variables, descriptive statistics will include the following information:  the number 
of patients reflected in the calculation (n), mean, median, SD, minimum, Q1, Q3, and maximum.   
For categorical or o rdinal data, frequencies and percentages will be displayed for each category.  
10.4.1.  Patient Disposition  
The following will be provided:  
 The total number of screened patients:  met the inclusion criteria regarding the target 
indication and signed the ICF  
 The tota l number of randomized patients:  received a randomization number  
 The total number of patients in each analysis set  
 The total number of patients who discontinued the study, and the reasons for 
discontinuation  
 A listing of patients treated but not randomiz ed, patients randomized but not treated, 
and patients randomized but not treated as randomized  
 A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation  
10.4.2.  Demography and Baseline Characteristics  
Demographic and bas eline characteristics will be summarized descriptively by [CONTACT_1570], 
and by [CONTACT_25048].   
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406618] 
model for repeated measure (MMRM) base d on the FAS with adjustment for missing data due to 
lack of efficacy or AEs assuming the scores would on average return to baseline values. The 
imputed data for patients discontinued from study drug due to lack of efficacy or AEs will be 
centered at the m ean baseline value.  The missing data for patients discontinued from treatment 
due to other reasons will be imputed under missing -at-random assumption.  
Missing data will be imputed 50 times to generate 50 complete data sets. Each imputed data set 
will be a nalyzed using the MMRM with terms for baseline score corresponding to the efficacy 
variable being analyzed, randomization strata (K -L category [2 to 3, or 4] and index joint [knee, 
hip]), treatment, visit, and treatment -by-visit interaction. The MMRM will be performed with an 
unstructured covariance matrix to model the within -patient errors. Denominator degrees of 
freedom will be estimated using Kenward -Roger’s approximation. The results from the 50 
analyses will be combined using Rubin’s formulae. The leas t-squares mean estimates for the mean 
change from baseline to week 16, as well as the difference of the estimates between fasinumab and 
placebo with their corresponding standard errors and associated 95% confidence intervals, will be 
provided.  
For analysi s of categorical variables, eg, proportions of patients with ≥30% improvement in the 
WOMAC pain subscale scores at week 16, the Cochran Mantel Haenszel approach stratified by 
[CONTACT_329131] -respons e. 
10.4.4.  Safety Analysis  
Safety data including nerve conduction measures, TEAEs  and treatment emergent AESIs, vital 
signs, physical exams, laboratory tests, ECGs, and ADA formation will be listed and summarized 
by [CONTACT_1570].  
Thresholds for potentially clinically significant values (PCSVs) in laboratory parameters and vital 
signs will be defined by [CONTACT_73493].  
The time interval to detect any AEs, including AESIs, is between the first dose of double -blinded 
study drug injection and the week  36 visit, as well as study drug -related SAEs occurring between 
the week 36 visit and the end of study.  
For safety variables, 3 observation periods are defined:  
 The pretreatment period is defined as the time from signin g the ICF to before the first 
dose of study drug.  
 The treatment period is defined as the day from first dose of study drug through the day 
of last dose (week  12) + 4 weeks.  
 The follow -up period is defined from the end of on -treatment period to the week  36 
visit.  
[IP_ADDRESS].  Primary Safety Analysis  
The variables for the evaluation of peripheral nerve function are the change from baseline to week 
16 in the amplitude and velocity from the 3 individual nerve conduction tests.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406619] errors and associated 95% confidence intervals, will be provided 
descriptively. Missing data due to no response or outside of test detection limit wil l be imputed 
using the first percentile of all non -missing values for that measurement prior to the MMRM 
analysis. Additional analysis based on observed data with no imputation may also be performed. 
Sensitivity analysis may be performed with data from all  patients including data collected after 
discontinuing treatment up to week 16.  
[IP_ADDRESS].  Adverse Events  
Definitions  
Treatment -emergent adverse events are defined as those that are not present at baseline or represent 
the exacerbation of a pre -existing condition du ring the on -treatment period.  
Analysis  
All AEs reported in this study will be coded using the currently available version of the Medical 
Dictionary for Regulatory Activities (MedDRA®).  Coding will be to lowest level terms.  The 
verbatim text, the preferre d term (PT), and the primary system organ class (SOC) will be listed. 
Post-treatment AEs and all AEs during the study will be summarized similarly as TEAEs.  
Summaries of all TEAEs by [CONTACT_12919]:  
 The number (n) and percentage (%) of patien ts with at least 1 TEAE by [CONTACT_3592]  
 TEAEs by [CONTACT_926] (according to the grading scale outlined in Section  9.5.1 ), 
presented by [CONTACT_3592]  
 TEAEs by [CONTACT_72843] (related, not related), presented by [CONTACT_3592]  
 Treatment -emergent AESIs (defined with a PT or a prespecified groupi[INVESTIGATOR_007])  
Deaths and other SAEs will be listed and summarized by [CONTACT_1570].  
Treatment -emergent adverse events lead ing to permanent treatment discontinuation will be listed 
and summarized by [CONTACT_1570].  
In addition, AESIs will be reported according to the adjudicated diagnosis.   Imaging data related 
to AA including change from baseline in joint space width will be  summarized.  
[IP_ADDRESS].  Other Safety  
Vital Signs  
Vital signs (temperature, pulse, blood pressure, and respi[INVESTIGATOR_1487]) will be summarized by 
[CONTACT_109994].  
Laboratory Tests  
Laboratory test results will be summarized by [CONTACT_25052].  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406620].  
Shift tables based on baseline normal/abnormal and other tabular and graphical methods may be 
used to present the results for laboratory tests of interest.  
Listings will be provided with flags indicating the out of laboratory range values.  
[IP_ADDRESS].  Treatment Exposure  
Because of the half -life of the biologic being studied, the duration of fasinumab exposure during 
the study will be presented by [CONTACT_25053]:  
(Date of last administration of study drug - date of the first study drug a dministration after 
randomization) + 28  
The number and percentage of patients randomized and exposed to double -blind study drug will 
be presented by [CONTACT_329132].   
[IP_ADDRESS].  Treatment Compliance  
Overall treatment compliance is defin ed as the actual dose of injection compared to the prescribed 
dose of treatment during the treatment period up to treatment discontinuation.  It is calculated 
according to the following formula:  
100* Total actual injection dose taken/Prescribed injection d ose. 
The total number of actual doses of fasinumab will be summarized.  
10.4.5.  Analysis of Drug Concentration Data  
Summaries of concentrations of functional fasinumab in serum will be presented descriptively by 
[CONTACT_329133]. Plots of individual concentration over time will be presented by [CONTACT_73501]. Plots of 
mean or median concentrations of functional fasinumab will be presented by [CONTACT_329134].  
No formal statistical analysis will be performed.  
10.4.6.  Analysis of Anti -Drug Antibody Data  
Immunogenicity will be cha racterized by [CONTACT_31607]:  
 Treatment -emergent ADA response  – defined as a ny post -dose positive ADA assay 
response when the baseline results are negative   
 Treatment -boosted ADA response – defined as any post -dose positive ADA assay 
response th at is 9 -fold over baseline titer levels when baseline is positive in the ADA 
assay  
 Maximum ADA titer values  
 Low (titer <1,000)  
 Moderate (1,000≤ titer ≤10,000)  
 High (titer >10,000)  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 72 of 83 
CONFIDENTIAL  Listings of ADA positivity and titers presented by [CONTACT_4676], time point, and dose group will be 
provided. Incidence  of treatment -emergent ADA response will be assessed as absolute occurrence 
(N) and percent of patients (%), grouped by [CONTACT_328762].  
The influence of ADAs on drug concentrations will be  evaluated.  Assessment of impact of ADAs  
on safety and efficacy may be provided.  
10.5. Interim Analysis  
An interim analysis may be performed after 50% patients have completed the 16 -week treatment 
period in order to assess peripheral nerve safety data for regulatory purposes.  
10.6. Additional Statistical Data Handling Conventions  
The following analysis and data conventions will be followed:  
General rules for handling missing data:  
 Rules for handling missing data for efficacy assessments due to missing individual  item 
data will follow each questionnaire’s instrument manual.  
 If the start date of an AE or concomitant medication is incomplete or missing, it will 
be assumed to have occurred on or after the intake of study medication, except if an 
incomplete date (eg, month and year) clearly indicates that the event started prior to 
treatment.  If the partial date indicates the same month or year of the intake of study 
medication date, then the start date by [CONTACT_197521]; 
otherwise, t he missing day or month by [CONTACT_197522].  
 No imputations for missing laboratory data, ECG data, vital sign data, or physical 
examination data will be made.  
Visit windows:  
 Assessments taken outside of protocol allowable w indows will be displayed according 
to the CRF assessment recorded by [CONTACT_093].  
Unscheduled assessments:  
 Extra assessments (laboratory data or vital signs associated with nonprotocol clinical 
visits or obtained in the course of investigating or mana ging AEs) will be included in 
listings, but not summaries.  If more than [ADDRESS_406621] observation will be used in summaries and all observations will be 
presented in listings.  
10.7. Statistical Considerations Surro unding the Premature Termination 
of a Study  
If the study is terminated prematurely, only those parameters required for the development 
program and/or reporting to regulatory authorities will be summarized.  Investigator and sponsor 
responsibilities surroun ding the premature termination of a study are presented in Section  16.1. 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 73 of 83 
CONFIDENTIAL  11. DATA MANAGEMENT AND ELECTRONIC SYSTEMS  
11.1. Data Management  
A data management pla n specifying all relevant aspects of data processing for the study (including 
data validation, cleaning, correcting, releasing) will be maintained and stored at Regeneron.  
A medical coding plan will specify the processes and the dictionary used for coding.  All data 
coding (eg, AEs, baseline findings, medication, medical history, surgical history) will be done 
using internationally recognized and accepted dictionaries.  
The eCRF  data for this study will be collected with an electronic data capture (EDC) tool,  Rave 
Medidata.  
11.2. Electronic Systems  
Electronic systems that may be used to process and/or collect data in this study will include the 
following:  
 IWRS system – randomization and study drug supply  
 Rave Medidata EDC system – clinical data capture  
 Statistical A nalysis System – statistical review and analysis  
 Argus - pharmacovigilance and clinical safety software system for the collection and 
reporting of SAEs and AESIs  
 Electronic Clinical Outcome Assessment systems – collected patient -reported or 
patient clinical assessment results  
 RAVE Medidata Imaging System  - electronic platform used to upload nerve 
conduction test  wave forms for central reader review  
12. STUDY MONITORING  
12.1. Monitoring of Study Sites  
The study monitor and/or designee (eg, CRO monitor) will visit each site prior to enrollment of 
the first patient, and periodically during the study.  
The investigator must allow study -related monitoring.  
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by [CONTACT_135713], complete, and verifiable from source documents, 
that the safety and rights of patients are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements.  
12.2. Source Document Requirements  
Investigators are required to prepare and maintain adequate and accurate patient records (source 
documents).  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406622] keep all source documents on fi le with the CRF (throughout this protocol, 
CRF refers to either a paper CRF or an electronic CRF). Case report forms and source documents 
must be available at all times for inspection by [CONTACT_25060].  
12.3. Case Report Form Requirements  
Study data obtained in the course of the clinical study will be recorded on electronic CRFs within 
the EDC system by [CONTACT_1146]. All required CRFs must be completed for each patient 
enrolled in the study. After re view of the clinical data for each patient, the investigator must 
provide an electronic signature. A copy of each patient CRF casebook is to be retained by [CONTACT_329135].  
The investigator must ensure the accuracy, completeness, and timeliness of the data reported to 
the sponsor in the CRFs.  
Corrections to the CRF will be entered in the CRF by [CONTACT_329136].  
All changes, including date and person performing corrections, will be available via the audit trail, 
which is part of the EDC system. For corrections made via data queries, a reason for any alteration 
must be provided.  
13. AUDI TS AND INSPECTIONS  
This study may be subject to a quality assurance audit or inspection by [CONTACT_25063].  Should this occur, the investigator is responsible for:  
 Informing the sponsor of a planned inspection by [CONTACT_50482], and authorizing the sponsor’s participation in the inspection  
 Providing access to all necessary facilities, study data, and documents for the inspection 
or audit  
 Communicating any information arising from inspection by [CONTACT_329137]  
 Taking all appropriate measures requested by [CONTACT_329138], CRFs, 
medical records, correspondence, ICFs, IRB or EC files, documentation of certification and quality 
control of supporting laboratories, and records relevant to the study maintained in any supporting 
pharmacy facilities.  Conditions of study mat erial storage are also subject to inspection.  In 
addition, representatives of the sponsor may observe the conduct of any aspect of the clinical study 
or its supporting activities both within and outside of the investigator's institution.  
In all instances,  the confidentiality of the data must be respected.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 75 of 83 
CONFIDENTIAL  14. ETHICAL AND REGULATO RY CONSIDERATIONS  
14.1. Good Clinical Practice Statement  
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accord ance with the ethical principles that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory 
requirements.  
14.2. Informed Consent  
The principles of informed consent are described in ICH  guidelines for GCP.  
The ICF used by [CONTACT_329139].  A copy of the IRB - or EC -approved ICF and 
documentation of approval must be provided to the sponsor before  study drug will be shipped to 
the study site.  
It is the responsibility of the investigator or designee (if acceptable by [CONTACT_427]) to obtain 
written informed consent from each patient prior to his/her participation in the study and after the 
aims, methods, objectives, and potential hazards of  the study have been explained to the patient  in 
language that he/she can understand.  The ICF should be signed and dated by [CONTACT_73510] . 
 Patients who can write but cannot  read will have the ICF read to them before signing 
and dating the ICF  
 Patients who can understand but who can neither write nor read will have the ICF read 
to them in presence of an impartial witness, who will sign and date the ICF to confirm 
that informe d consent was given  
The original ICF must be retained by [CONTACT_31616] 's study record, and a 
copy of the signed ICF must be given to the patient . 
If new safety information results in significant changes in the risk/benefit assessm ent, the ICF must 
be reviewed and updated appropriately.  All study patient s must be informed of the new 
information and provide their written consent if they wish to continue in the study. The original 
signed revised ICF must be maintained in the patient ’s study record and a copy must be given to 
the patient . 
14.3. Patient  Confidentiality and Data Protection  
The investigator must take all appropriate measures to ensure that the anonymity of each study 
patient will be maintained. Patient s should be identified by [CONTACT_73511], 
only, on CRFs or other documents submitted to the sponsor. Documents that will not be submitted 
to the sponsor (eg, signed ICF) must be kept in strict confidence.  
The patient 's identifiers and investigator's personal data, which may be included in the sponsor 
database, will be treated in compliance with all applicable laws and regulations. The sponsor shall 
take all appropriate measures to safeguard and prevent access to this data by [CONTACT_329140].  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406623]/Ethics Committee  
An appropriately constituted IRB or EC, as described in ICH guidelines for GCP, must review and 
approve:  
 The protocol, ICF, and any other materials to be provided to the patients 
(eg, advertis ing) before any patient  may be enrolled in the study  
 Any amendment or modification to the study protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the patient s, in 
which case the IRB or EC should be in formed as soon as possible  
 Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the IRB or EC should be informed of any event likely to affect the safety of patient s 
or the continued conduct of the clinical st udy. 
A copy of the IRB - or EC -approval letter with a current list of the IRB or EC members and their 
functions must be received by [CONTACT_25069].  
The approval letter should include the study number and title, the documents reviewed, and the 
date of the review.  
Records of the IRB or EC review and approval of all study documents (including approval of 
ongoing st udies) must be kept on file by [CONTACT_093].  
14.5. Clinical Study Data Transparency  
Final study re sults will be published on a public clinical trial website according to applicable local 
guidelines and regulations.   Treatment codes will be disseminated to each investigation site 
thereafter.  
15. PROTOCOL AMENDMENTS  
The sponsor may not implement a change in the design of the protocol or ICF without an IRB - or 
EC-approved amendment. Regulatory approval will also be obtained where required by [CONTACT_13125].  
16. PREMATURE TERMINATIO N OF THE STUDY OR 
CLOSE -OUT OF A SITE  
16.1. Premature Termination of the Study  
The spon sor has the right to terminate the study prematurely. Reasons may include efficacy, safety, 
or futility, among others. Should the sponsor decide to terminate the study, the investigator(s) will 
be notified in writing.  
16.2. Close -out of a Site  
The sponsor and th e investigator have the right to close -out a site prematurely.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 77 of 83 
CONFIDENTIAL  Investigator’s Decision  
The investigator must notify the sponsor of a desire to close -out a site in writing, providing at least 
30 days’ notice.  The final decision should be made through mutual agreement with the sponsor.  
Both parties will arrange the close -out procedures after review and consultation.  
Sponsor’s Decision  
The sponsor will notify the investigator(s) of a decision to close -out a study site in writing.  
Reasons may include th e following, among others:  
 The investigator has received all items and information necessary to perform the study, 
but has not enrolled any patient  within a reasonable period of time  
 The investigator has violated any fundamental obligation in the study ag reement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelines  
 The total number of patient s required for the study are enrolled earlier than expected  
In all cases, the appropriate IRB or EC and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be given to the protection of 
the patient s’ interests.  
17. STUDY DOCUMENTATIO N 
17.1. Certification of Accuracy of Data  
A declaration assuring the accuracy and content of the data recorded on the eCRF must be signed 
electronically by [CONTACT_093]. This signed declaration accompanies each set of patient final 
eCRF  that will be provided  to the sponsor.  
17.2. Retention of Records  
The investigator must retain all essential study documents, including ICFs, source documents, 
investigator copi[INVESTIGATOR_3110], and drug accountability records for at least [ADDRESS_406624] be destroyed in a manner that ensures 
confidentiality.  
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the sponsor (written notific ation) and the relevant records will be 
transferred to a mutually agreed -upon destination.  
18. DATA QUALITY ASSURAN CE  
In accordance with ICH E6, the sponsor is responsible for quality assurance to ensure that the 
study is conducted and the data generated, re corded, and reported in compliance with the protocol, 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 78 of 83 
CONFIDENTIAL  GCP, and any applicable regulatory requirement(s).  The planned quality assurance and quality 
control procedures for the study are summarized.  
Data Management  
The sponsor is responsible for the data ma nagement of this study including quality checking of the 
data (Section  11.1). 
Study Monitoring  
The investigator must allow study -related monitoring, IRB/EC review, audits, and inspections 
from relevant health regulatory authorities, and provide direct access to source data documents 
(Section  12.1, Section  12.2, and Section  13). 
The stu dy monitors will perform ongoing source data review to verify that data recorded in the 
CRF by [CONTACT_1191], complete, and verifiable from source documents, 
that the safety and rights of patients are being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements (Section  12.1). 
All patient data collected during the study will be recorded on paper or electronic CRF unless the 
data are transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator 
is responsible for affirming that data entries in the CRF are accurate and correct by [CONTACT_50485] a declaration that accompanies each set of patient final CRF (Section  12.3, Section  17.1).  
Study Documentation  
The investigator must maintain accurate documentation (source data) that supports the information 
entered in the CRF (Section  12.2).  
The investigator will retain all records and documents, including signed ICF s, pertaining to the 
conduct of this study for at least 15 years after study completion, unless local regulations or 
institutional policies require a longer retention period.  No records may be destroyed during the 
retention period without the written appr oval of the sponsor. No records may be transferred to 
another location or party without written notification to the sponsor (Section  17.2).  
19. CONFIDEN TIALITY  
Confidentiality of information is provided as a separate agreement.  
20. FINANCING AND INSURA NCE  
Financing and insurance information is provided as a separate agreement.  
21. PUBLICATION POLICY  
The publication policy is provided as a separate agreement.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 79 of 83 
CONFIDENTIAL  22. REFERENCES  
Aloe, L., M.A. Tuveri, U. Carcassi, and R. Levi -Montalcini. Nerve growth factor in the synovial 
fluid of patients with chronic arthritis. Arthritis Rheum. 1992. 35:351 -355. 
Altman, R., G. Alarcon, D. Appelrouth, D. Bloch, D. Borenstein, K. Brand t, C. Brown, T.D. 
Cooke, W. Daniel, D. Feldman, and et al. The American College of Rheumatology criteria for the 
classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991. 34:505 -514. 
Altman, R., E. Asch, D. Bloch, G. Bole, D. Borens tein, K. Brandt, W. Christy, T.D. Cooke, R. 
Greenwald, M. Hochberg, and et al. Development of criteria for the classification and reporting of 
osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria 
Committee of th e American Rheumatism Association. Arthritis Rheum. 1986. 29:1039 -1049.  
Available  at: 
http://www.rheumatology.org/Portals/1030/Files/Complete%1020Article_Osteoarthritis%1020of
%1020the%1020Knee%1020 -%201986.pdf.  
Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for 
treating painful diabetic peripheral neuropathy: A double -blind placebo -controlled trial. BMC 
Neurology 2008. 8:[ADDRESS_406625], S.S. Smugar, B. J. 
Fitzgerald, K. O'Brien, and A.M. Tershakovec. Efficacy and safety of etoricoxib 30 mg and 
celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, 
placebo -controlled, non -inferiority studies. Rheumatology (Oxford). 20 07. 46:496 -507. 
Bjordal, J.M., A.E. Ljunggren, A. Klovning, and L. Slordal. Non -steroidal anti -inflammatory 
drugs, including cyclo -oxygenase -2 inhibitors, in osteoarthritic knee pain: meta -analysis of 
randomised placebo controlled trials. BMJ. 2004. 329:[ADDRESS_406626]. Tanezumab 
reduces osteoarthritic knee pain: results of a randomized, double -blind, placebo -controlled phase 
III trial. J Pain. 2012. 13:790 -798. 
Chao, M.V., R. Rajagopal, and  F.S. Lee. Neurotrophin signaling in health and disease. Clinical 
Science. 2006. 110:167 -173. 
Crowley, C., S.D. Spencer, M.C. Nishimura, K.S. Chen, S. Pi[INVESTIGATOR_7929] -Meek, M.P. Armanini, L.H. Ling, 
S.B. McMahon, D.L. Shelton, A.D. Levinson, and et al. Mice lacking nerve growth factor display 
perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. 
Cell. 1994. 76:[ADDRESS_406627] of osteoarthritis pain in the workforce: results from the National Health and Wellness 
Survey. BMC Musculoskelet Disord. 2011. 12:83.  
Dolgin, M., Editor. 1994. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and 
Great Vessels. In The Criteria  Committee of the [LOCATION_001] Heart Association, 9th Edition. Little, 
Brown, and Co., [LOCATION_011], MA. 253 -256. 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 80 of 83 
CONFIDENTIAL  Einarsdottir, E., A. Carlsson, J. Minde, G. Toolanen, O. Svensson, G. Solders, G. Holmgren, D. 
Holmberg, and M. Holmberg. A mutation in the nerve growth  factor beta gene (NGFB) causes 
loss of pain perception. Hum Mol Genet. 2004. 13:799 -805. 
Halliday, D.A., C. Zettler, R.A. Rush, R. Scicchitano, and J.D. McNeil. Elevated nerve growth 
factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res. 
1998. 23:919 -922. 
Harris, W.H. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by 
[CONTACT_73513]. An end -result study using a new method of result evaluation. J Bone Joint Surg 
Am. 1969. 51:73 7-755. 
Hefti, F., M. Mokhtarani, M. Gray, C. Zhao, and C. Chan. RN624 (Anti -NGF) reduces pain and 
improves function in subjects with moderate to severe pain form osteoarthritis of the knee. The 
Journal of Pain. 2006. 7:S46.  
Indo, Y., M. Tsuruta, Y. Hayashi da, M.A. Karim, K. Ohta, T. Kawano, H. Mitsubuchi, H. Tonoki, 
Y. Awaya, and I. Matsuda. Mutations in the TRKA/NGF receptor gene in patients with congenital 
insensitivity to pain with anhidrosis. Nat Genet. 1996. 13:485 -488. 
Insall, J.N., L.D. Dorr, R.D. Sc ott, and W.N. Scott. Rationale of the Knee Society clinical rating 
system. Clin Orthop Relat Res. 1989.13 -14. 
Katz, N., D.G. Borenstein, C. Birbara, C. Bramson, M.A. Nemeth, M.D. Smith, and M.T. Brown. 
Efficacy and safety of tanezumab in the treatment of c hronic low back pain. Pain. 2011. 152:[ADDRESS_406628], and 
K.M. Verburg. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low 
back pain. Pain. 2013.  154:1009 -1021.  
Lanas, A. Gastrointestinal bleeding associated with low -dose aspi[INVESTIGATOR_34308]: relevance and 
management in clinical practice. Expert Opin Drug Saf. 2011. 10:[ADDRESS_406629], N.E., T.J. Schnitzer, C.A. Birbara, M. Mokhtarani, D.L. Shelton, M.D. Smith , and M.T. 
Brown. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010. 
363:1521 -1531.  
Lewin, G.R., A. Rueff, and L.M. Mendell. Peripheral and central mechanisms of NGF -induced 
hyperalgesia. Eur J Neurosci. 1994. 6:[ADDRESS_406630] JM. Neurotrophin 3 improves delayed 
reconstruction of sensory pathways after cervical dorsal root injury. Neurosurgery. 2011 
Feb;68(2):450 -61 
Lowe, E.M., P. Anand, G. Terenghi, R.E. Williams -Chestnut , D.V. Sinicropi, and J.L. Osborne. 
Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory 
urgency and interstitial cystitis. Br J Urol. 1997. 79:572 -577. 
Makarowski, W., W.W. Zhao, T. Bevirt, and D.P. Recker. Efficacy  and safety of the COX -2 
specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double -
blind, placebo -controlled comparison with naproxen. Osteoarthritis Cartilage. 2002. 10:290 -296. 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 81 of 83 
CONFIDENTIAL  Mallik A, Weir AI. Nerve conduction studies: Essentials and pi[INVESTIGATOR_329092]. J Neurol 
Neurosurg Psychiatry. 2005. 76(Suppl II): ii23 -ii31. 
McArthur, JC, Yiannoutsos C, Simpson D, Adornato BT, Singer EJ, Hollander H, et al. A phase 
II trial of nerve growth factor for sensory neuropathy a ssociated with HIV infection. AIDS Clinical 
Trials Group Team 291. Neurology. 2000. 54:1080 -1088.  
Miller LJ, Fischer KA, Goralnick SJ, MLitt M, Burleson JA, PAlbertsen P, et al. Nerve growth 
factor and chronic prostatitis/chronic pelvic pain syndrome. Urol ogy. 2002. 59:603 -608. 
Parkman HP, Rao SS, Reynolds JC, Schiller LR, Wald A, Miner PB et al. Neurotrophin -3 
improves functional constipation.  Am J Gastroenterol. 2003 Jun;98(6):1338 -47. 
Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain.  Annu Rev Neurosci. 
2006. 29:507 -538. 
Ramer MS, Bisby [CONTACT_78729]. Adrenergic innervation of rat sensory ganglia following proximal or distal 
painful sciatic neuropathy: distinct mechanisms revealed by [CONTACT_14181] -NGF treatment. Eur J Neurosci. 
1999. 11:[ADDRESS_406631] of 
lower -limb osteoarthritis worldwide: a systematic review of cost -of-illness studies. Osteoarthritis 
Cartilage. 2016. 24:1500 -1508.  
Sarchielli P, Alberti A, Floridi A, Gallai V . Levels of nerve growth factor in cerebrospi[INVESTIGATOR_329093]. Neurology. 2001. 57:132 -134. 
Sarzi -Puttini P, Cimmino MA, Scarpa R, RCaporali R, Parazzini F, Zaninelli A, et al. 
Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum. 
2005. 35:1 -10. 
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pi[INVESTIGATOR_35807] T, Whelton A, et al. Gastrointestinal 
toxicity with celecoxib vs nonsteroidal anti -inflammatory drugs for osteoarthritis and rheumatoid 
arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long -term Arthritis Safety 
Study. JAMA. 2000. 284:1247 -1255.  
Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, et al. Severe sensory and 
sympathetic neuropathies in mice carrying a d isrupted Trk/NGF receptor gene. Nature. 1994. 
368:246 -249. 
Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular 
safety of non -steroidal anti -inflammatory drugs: network meta -analysis. BMJ. 2011. 342:c7086.  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:[ADDRESS_406632] IGATOR’S AGREEMENT  
I have read the attached protocol, entitled “A Randomized, Double -Blind, Placebo -Controlled, 
Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients 
with Pain due to Osteoarthritis of the Knee or H ip,” dated as noted in the appended signature [CONTACT_3264], 
and agree to abide by [CONTACT_3769].  
I agree to comply with the current International Council for Harmonisation Guideline for Good 
Clinical Practice and the laws, rules, regulations, an d guidelines of the community, country, state, 
or locality relating to the conduct of the clinical study.  
I also agree that persons debarred from conducting or working on clinical studies by [CONTACT_50487] a partnership 
in which the sponsor is involved.  I will immediately disclose it in writing to the sponsor if any 
person who is involved in the study is debarred, or if any proceeding for debarment is pending, or, 
to the b est of my knowledge, threatened.  
This document contains confidential information of the sponsor, which must not be disclosed to 
anyone other than the recipi[INVESTIGATOR_329094].  I agree to ensure that this information will not be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of the sponsor.  
   
(Signature [CONTACT_7919])   (Date)  
   
(Printed Name)    
 
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Clinical Study Protocol   R475 -OA-1758 Amendment 2  
Regeneron Pharmaceuticals, Inc.   Page 83 of 83 
CONFIDENTIAL  SIGNATURE [CONTACT_11715]’S RESPONSIBL E OFFICERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Team Lead, and 
Biostatistician)  
To the best of my knowledge, this report accurately describes the conduct of the study.  
Study Title:  A Randomized, Double -Blind, Placebo -Controlled, Multicenter Study to 
Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients 
with Pain Due to Osteoarthritis of the Hip or Knee  
Protocol Number:  R475 -OA-1758  
Protocol Version:  R475 -OA-1758 Amendment 2  
 
See appended electronic signature [CONTACT_25085]’s Responsible Medical/Study Director  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Regulatory Liaison  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Clinical Study Team Lead  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Biostatistician  
                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
Signature [CONTACT_11032]-RIM-00063020 v2.0
Signature [CONTACT_11032]-RIM-00063020 v2.0 ApprovedESig Approval
00
ESig Approval
-2019 17:04:45 GMT[PHONE_006]
ESig Approval
-2019 17:53:27 GMT[PHONE_006]
ESig Approval
19 19:09:00 GMT[PHONE_006]                                        VV-RIM-00063020-2.0 Approved - 19 Feb 2019 GMT-5:00
